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ABSTRACT
The pediatric mental health burden in the United States (US) is substantial,
with more than 4 million children meeting diagnostic criteria for a mental health
disorder. As of 2014, this number represented 20% of US children and adolescents.
In 2010, mental health disorders are estimated to cost children and their families $247
billion dollars annually and severely impact quality of life for children and their
families. From 2007 to 2010, inpatient admissions for mental health disorders in
pediatric patients increased 24% and mood disorder admissions in pediatric patients
increased 80% from 1997-2010. An estimated $11.6 billion was spent on pediatric
mental health hospitalizations from 2006 through 2011, with public sources such as
Medicaid and Medicare responsible for approximately 50% of the payments, leaving
50% to private payers. This economic and clinical concern has led pediatric medical
associations and health quality agencies to increase support and funding for pediatric
mental health research and treatment.
Medication therapy is a common intervention in mental health treatment and
atypical antipsychotics are increasing in utilization, often becoming first-line therapy.
Despite available data describing the need to treat pediatric mental health conditions,
the available evidence for clinical effectiveness and economic impact of atypical
antipsychotics (AAPs) has many shortfalls. Most available research is derived from
patients utilizing publicly-funded medical care, such as Medicaid or Medicare
resources, with little data available about patients with privately-funded care. To help
address this gap in the literature, we used a large, privately-insured, US population for
our analysis. We examined if the increased trend in AAP utilization from previous

research is also present in this pediatric population. Considering the payer perspective,
we evaluated the cost of AAP medication therapy based on most recent utilization.
Available studies lack information about the direct costs of pediatric mental
health treatment and efficacy of psychiatric medications in the pediatric population.
Most efficacy studies are based on clinical trials necessary for pediatric indication
approval from regulatory agencies such as the Food and Drug Administration (FDA).
Many of the AAP medications do not have pediatric clinical trial evidence available
and are frequently utilized without pediatric indications. The available data suggests
that off-label prescribing is not an uncommon practice in the pediatric patient
population.3,4
Approximately half of atypical antipsychotics do not have pediatric indications
but are increasingly used, particularly in treating behavior disorders, due to such
factors as improved patient compliance and improved side effect profiles. Limited
formal studies examining atypical antipsychotic use compared to other agents in the
class have been conducted. Studies with direct comparisons have yet to be conducted
in the pediatric population with mental health disorders.
The manuscripts that comprise this dissertation aim to provide new insights
into available trend and utilization patterns of atypical antipsychotic medication use in
children. This research characterized the prevalence of atypical antipsychotic use in
pediatric patient with mental health conditions in a large, privately insured US
population, evaluating the diagnoses associated with treatment and estimate the cost of
AAP medication therapy in this population. This research determined if the trends
observed in publicly-insured children persist in the privately-insured, pediatric patient.

The analysis evaluated annual trends in prevalent use of atypical antipsychotic
medication over 6-year period in this pediatric population and evaluated the
appropriate use of AAPs for mental health diagnoses. Lastly, an evaluation
determined if specific antipsychotic therapy delayed time to readmission among
privately-insured children following a psychiatric hospital admission. The results of
this dissertation will provide new insights regarding the trends and direct medication
costs of atypical antipsychotic agents when utilized in pediatric patients with mental
health disorders.
Manuscript 1: This analysis focused on characterizing the most recent (2015)
AAP use in the pediatric population with mental health disorders, using a large, US
population of privately- insured children. The study evaluated if the prevalence data
observed among publicly insured children persists. Characterization of the prescribing
trends for atypical antipsychotics and the medication costs of the use in this population
were examined. Patterns of use across demographics and associated mental health
diagnoses were characterized by the class of medication. This study focused on the
prevalent use of AAPs in pediatric patients with a mental health diagnosis, evaluated
the mental health diagnoses associated with AAPs and the direct cost burden of
medication therapy associated with this use of AAP in the pediatric population to the
private payer.
Manuscript 2: This research evaluated the trends in the prescribing of atypical
antipsychotic medications from 2010 through 2015 in this privately-insured pediatric
population. The trends of AAP use in the pediatric population over six years were
examined. The associated mental health diagnoses corresponding with AAP

prescribing were described to examine the off-label diagnoses treatment prevalence in
this population. This study hypothesizes that the prevalent use of AAPs is increasing
in the privately-insured patients and off-label prescribing accounts for most clinical
use in pediatric patients.
Manuscript 3: This analysis examined pediatric patients who utilized oral
atypical antipsychotic therapy after an inpatient admission for mental health treatment.
Readmission for mental health treatment was evaluated to determine the efficacy of
using oral AAP medications in pediatric mental health patients. Some oral AAP
agents have shown benefit in pediatric patients compared to placebo and have an
official FDA indication for pediatric use. Many clinical providers believe that this
entire class of medications can demonstrate benefit in pediatric patients, regardless of
FDA indication. This study hypothesized that certain oral AAP medications are
associated with delayed readmission in pediatric patients with an index admission for
mental health treatment.
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PREFACE
For this dissertation, a manuscript format will be utilized and will be comprised
of three manuscripts, which examined (1) the current utilization and costs of atypical
antipsychotic use in pediatric patients with mental health diagnoses, (2) the trend in
atypical antipsychotic prescribing in the pediatric population and off-label prescribing
of these agents, (3) the effectiveness of oral atypical antipsychotic agents in delaying
inpatient readmission for mental health treatment in pediatric patients.
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1.1 Abstract
BACKGROUND: Atypical antipsychotics (AAPs) are one of the most commonly
prescribed classes of medication in the United States, representing 5% of all
prescriptions among both pediatric and adult populations in 2012. The overall use of
AAPs in pediatric patients with mental health disorders has been increasing over the
last 20 years. Since 2007, almost double the number of AAPs have been approved on
the US market and utilized in the pediatric population.1 However, most available
utilization studies are dated with the most recent completed almost ten years ago. The
pediatric mental health burden in the United States (US) is substantial, with more than
4 million children meeting diagnostic criteria for a mental health disorder. As of
2014, this number represented 20% of US children. In 2010, mental health disorders
are estimated to cost youth and families $247 billion. This study aims to provide a
current (2015) assessment of atypical antipsychotic use in pediatric patients.
OBJECTIVE: This study will determine the prevalence and costs of atypical
antipsychotic medication therapy in the privately-insured pediatric patient population
with a mental health disorders. This study will also identify patient and clinical
characteristics that influence the use of atypical antipsychotic medication in pediatric
patients with mental health diagnoses.
METHODS: Healthcare claims data extracted from the Optum Clinformatics ® Data
Mart; (OptumInsight, Eden Prairie, MN) database between January 2015 and
December 2015 were analyzed. Children and adolescents (2-17 years) with a mental
health diagnosis of interest, regardless of the presence of a paid claim for an atypical
antipsychotic medication, were included. Baseline characteristics of patients by AAP
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medication use (received AAP medications anytime during the year versus none
during the year) were determined and prevalence of AAP use was calculated.
Predictors of AAP medication use were evaluated using a logistic regression model.
Twelve-month average costs for AAP therapy was calculated for the AAP medication
cohort using a linear regression model.
RESULTS: The one-year prevalence in the privately-insured, pediatric population
with a mental health disorder was 7% (67.5 per 1,000 children) in 2015. Despite
being selected for inclusion in the cohort by mental health diagnosis of interest, we
found that 29% of children treated with AAP medications did not have a mental health
diagnosis at associated medical visit. Specialty providers were responsible for 41% of
the AAP prescribing and found that primary care providers only prescribed 17% of the
AAP paid claims. In the cost analysis, the average per member per month (PMPM)
cost for the entire study population was $311.58. The total 12-month spend for 35,311
paid claims for AAP medication therapy was $12.5 million in 2015, representing
5,253 unique patients over the study period. Formulation of aripiprazole (generic and
name brand) were the most commonly prescribed atypical antipsychotic medication
(42%) followed by generic risperidone (25%) in 2015. The median cost of a paid
claim for generic risperidone was $21.04 (Q1 = $12.39, Q3 = $31.55) per claim,
representing almost the lowest cost per claim of all the AAP agents. The median cost
of a paid claim for generic aripiprazole was $531.23 (Q1 = $519.79, Q3 = $668.89)
per claim, representing the highest cost per paid claim compared with all other
available generic AAP agents.
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CONCLUSIONS: The prevalence of using atypical antipsychotic medications in
pediatric patients with mental health disorders is significant in the privately-insured
population. Individual costs vary greatly by AAP medication and further costs studies
are warranted to determine the potential economic impact to a specific private payer.
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1.2 Introduction
The pediatric mental health burden in the United States (US) is substantial,
with more than 4 million children meeting diagnostic criteria for a mental health
disorder.2–4 As of 2014, this number represented 20% of US children. Pediatric
patients are defined as children from 2 to 12 years and adolescents from 13 to 18
years.5 In 2010, mental health disorders are estimated to cost youth and families $247
billion dollars annually and severely impact quality of life for children and their
families.2–4,6 An estimated $11.6 billion was spent on pediatric mental health
hospitalizations from 2006 through 2011, with public sources such as Medicaid and
Medicare responsible for approximately 50% of the payments, leaving 50% to private
payers.7 This economic and clinical concern has led pediatric medical associations
and health quality agencies to increase support and funding for pediatric mental health
research and treatment.2,7
Antipsychotic medication therapy is the gold standard of treatment for
psychosis and related behavior disorders in adult patients. In the past decade, these
medications have gained popularity as treatments for psychiatric and behavior
disorders in adolescents (13-<18 years old) and pediatric patients (2-<13 years old),
despite gaps in clinical efficacy and safety research.8–10 Pediatric patients with
behavioral and affective disorders, autism-spectrum disorders and mood disorders
often benefit from pharmacotherapy with antipsychotic agents in conjunction with
other nonpharmacological interventions.10–13 While not all atypical antipsychotics
have an Food and Drug Administration (FDA) indication for use in pediatric patients,
atypical antipsychotics are considered first line agents by mental health experts and
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clinicians, compared to typical antipsychotic medications, due to improved side effect
and safety profiles, as demonstrated in adult clinical trials. 13 A Cochrane review of
atypical antipsychotics in patients under the age of 18 years found only 13 suitable
randomized, controlled trials appropriate for inclusion, representing 1,100 pediatric
patients in total.14 There is a lack of sufficient evidence regarding the comparative
effectiveness of atypical agents over traditional agents in pediatric patients.14 AAP
medications offer the possibility of benefit in pediatric patients; however, there is
limited evidence to support widespread use of these agents.
As of 2012, AAPs are one of the most commonly prescribed classes of
medication in the United States, representing 5% of all prescriptions among both
pediatric and adult populations and over $13 billion in drug expenditures.13 The
overall trend of use for AAP in pediatric patients with mental health disorders has
been increasing over the last 20 years. From 1995 to 2002, multiple studies
demonstrated a 5-fold increase of antipsychotic use in pediatric and adolescent
patients in the United States.14,15 This trend was largely due to the increased
availability of atypical antipsychotics and the common misconception that atypical
antipsychotics demonstrated lower risk of serious adverse events.16,17 From 2007 to
2010, a study evaluating off-label use of AAP medications, found that 12% of
outpatient medical visits documented the use of AAPs. This utilization study was
based on medical visits where AAP medications were documented and not on paid
claims data. More recent trend data utilizing administrative claims data in privatelyinsured children is unavailable. Cooper et al examined antipsychotic mediation use in
publicly-insured youth and found that 53% of incident users were being treated for
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mood or behavior disorders and not traditional psychiatric conditions.8,15,16,18
Utilization and medication costs can vary over time based on market changes. Since
2007, almost double the number of AAPs have been approved on the US market and
have been utilized in the pediatric population, according to claims database analyses.1
However, most available measures of prevalent use are somewhat dated with the most
recent completed studies analyzing data only as recent as 2011.12
Medication therapy is a common intervention in mental health treatment and
atypical antipsychotics are increasing in use and often a first-line therapy.3,7,9 Despite
available data describing the need to treat pediatric mental health conditions, the
available evidence for clinical effectiveness and economic impact of atypical
antipsychotics (AAPs) has many shortfalls. As of 2010, most of the trend studies
focused on publicly-insured children, such as Medicaid enrollees, with few studies
including large, privately-insured populations. The available data suggests a growing
trend in atypical antipsychotic use in pediatric patients with mental health diagnoses,
but only a limited number of studies evaluated use of this medication class among
privately-insured patients. It is unclear whether the available prevalence of AAP use
among publicly insured children is also comparable to that among privately-insured
pediatric populations with mental health diagnoses.8,16,18,19
The goal of this study is to characterize AAP use in the pediatric population
with mental health diagnoses, using a large, US population of privately-insured
children. Characterization of the prescribing prevalence for atypical antipsychotics and
the medication costs of the use in this population will be examined. Examining this
population for changes in prescribing over the most recent year can provide additional
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insight into spending trends and changes in payer spending for AAP therapy. This
study will evaluate how new market entries and new generic medications have
possibly changed the spending profile and may provide additional data on the
medication costs differences seen in this study compared to available literature.
Patterns of use across demographics and associated mental health diagnoses will be
described to better characterize the use of this class of medication in the pediatric
population with mental health diagnoses. Considering the payer perspective, we
evaluated the direct cost burden of AAP medication therapy for 2015, the most recent
year of available data. We evaluated the overall utilization of these medications among
privately-insured pediatric patients with mental health diagnoses. We discuss a
comparison of the overall utilization observed in our study to available reported
utilization among publicly-insured children.
1.3 Methods
Data Source and Study Design
This cross-sectional study was conducted utilizing administrative data (Optum
Clinformatics ® Data Mart; OptumInsight, Eden Prairie, MN) for the period of
January 1, 2015 to December 31, 2015. This data includes commercial health
insurance claims (inpatient and outpatient medical records, laboratory data, facility
information, and outpatient pharmacy) and enrollment data from large, private insurer
across the United States.20 This dataset provides healthcare information on 36 million
beneficiaries and encompasses 1.2 billion individual medical records.
Sample selection
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We conducted a cross-sectional study of atypical antipsychotic use among US
pediatric enrollees to describe the use of atypical antipsychotic medication as most
recently prescribed during the calendar year 2015. Our analyses were conducted using
pharmacy claims data, outpatient medical claims data and patient eligibility data,
which included patient age, gender, geographic region. Pharmacy claims data included
medication information such as days’ supply, quantity, prescribing physician and cost
data. Outpatient medical visit provided clinical information on date of service,
diagnosis codes at time of visit and provider type. Figure 1 displays a flowchart of
inclusion and exclusion criteria. Each patient was required to have at least one
medical record present in 2015 with a mental health diagnosis of interest and
information was aggregated to patient level (Appendix A). There were 87,503
pediatric patients with at least one mental health diagnosis enrolled in dataset in 2015.
Pediatric patients (ages 2-17 years) represented 10% of the population available for
analysis in administrative database. Before exclusion criteria were applied, 23%
(20,732) of patients had a diagnosis of Disruptive or Aggressive Behavior (DAB)
Disorders, 14% (11,870) had a diagnosis of Anxiety Disorders and 13% (11,611) had
a diagnosis of Developmental Disorders (Table 1). Of the entire original cohort, 0.3%
(210) of patients had a diagnosis of six mental health diagnostic categories
documented at a medical visit claim during 2015.
Patients were excluded from study for the following conditions: 18 years or
older during study period, did not have continuous enrollment during study period or
incomplete information available for paid claims or medical visits for analysis. All

9

available dosage forms and atypical antipsychotic medications were included in the
analysis, regardless of indicated use for the pediatric population.
Outcomes
For determination of atypical antipsychotic prescription use, the most recent
dispensing of this medication type was used. Patients were identified as having an
AAP medication paid claim using National Drug Codes (NDCs) as provided in
Appendix B, for an available AAP medications on the US market. If patients had
more than one paid claim for an AAP, we selected the most recent paid claim (latest
fill date in 2015) to represent the paid claim of interest to best represent the most
relevant clinical treatment plan.
For the cost analysis, the total cost of AAP medication therapy was determined
as a summation of all paid claims for AAP medications for individual pediatric
patients with mental health diagnoses over the calendar year 2015. To determine the
12-month average spend for atypical antipsychotic medication therapy, a per-member
per-month (PMPM) variable was determined based on patient’s overall days of
exposure to AAP medication therapy and total cost of AAP therapy for each patient.
The PMPM was calculated by totaling the cost for all paid claims for a given patients
and dividing by total day supply of AAP medication therapy. This value was then
multiplied by 30 days to represent the monthly cost associated with AAP medication
therapy for each patient. This value provides a mean cost per patient for all AAP
medications received per month, regardless of number of claims represented.
Statistical Analysis

10

The prevalence of AAP use was examined by age group (2 to 5 years, 6 to 12
years, 13 to 17 years), gender, geographic region (Northeast, Midwest, West and
South), primary mental health diagnosis closest to the AAP paid claim date
(Appendix A), provider category and concomitant medication use, including
anxiolytics, antidepressants, antiepileptics and stimulants. Concomitant medication
therapy was defined as the presence of a paid claim for the medication class of interest
during the study period of 2015. This study focused on overall utilization of atypical
antipsychotics and did not examine therapy switching between agents or overlap of
multiple AAPs because this information is not needed to characterize the current
utilization of any AAP agent. Mental health diagnoses were treated as a categorical
variable, with an indicator variable for each condition as listed in Appendix A, using
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD9-CM) and Tenth Revision (ICD-10-CM) diagnostic codes. Several studies examining
mental health ICD-9 codes for research have been performed and indicate strong
validity in using these codes in claims data mental health research.21,22 Davis et. al
found a positive predictive value (PPV) of 76% for mental health condition in
administrative claims data.22 Several previous research groups used these diagnostic
categories for administrative data analysis of pediatric mental health conditions.9,15,22
To determine the diagnosis associated with a specific AAP paid claim, a 60-day
window (60 days before and after) around the date of prescription fill was established
and the closest medical visit was selected to ascertain the diagnoses. If the 60 days
window fell outside the study period, then patients were excluded for not having
sufficient data for complete analysis. For patients that received no AAP therapy in
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2015, the diagnoses from the most recent medical provider visits in 2015 were used.
Per medical visit, only the first ten fields were used because these captured 95% of
available diagnosis information in the database.
Among pediatric patients with mental health diagnoses, we determined the
frequency and percentage of patients with AAP use compared to those without AAP
therapy in 2015. Differences in patient characteristics and prescription claim
information between the two groups were determined using the Chi-Square test.
Prevalence was calculated as the number of pediatric patients with mental health
diagnoses receiving a pharmacy dispensing for at least one AAP medication divided
by the total number of children with a mental health diagnosis of interest during 2015.
A logistic regression model was used to determine the factors associated with the use
of AAP medication therapy. All pairwise interactions between covariates were tested
and none were found to be statistically significant. No interaction terms were included
in the final model due to lack of statistical significance. Collinearity between
independent variables was tested using Variance Inflation Factors (VIF) test and no
significant collinearity was found. No adjustments for collinearity were made in the
final model. We evaluated the associations in both unadjusted and adjusted models
that also included gender, age, geographical region, concomitant medication uses and
provider specialty. Covariates with a P value < 0.20 in the univariate model were
included in the final adjusted model, with primary mental health diagnosis forced into
the model due to known clinical relevance for AAP therapy use.
The direct cost burden of medication therapy for pediatric patients with mental
health conditions was analyzed as a percentage of the total spend for pediatric patients
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with mental health disorders of interest over the study period. To assess the 12-month
average cost for AAP medication therapy per patient, the PMPM variable was chosen,
to represent the most accurate average cost per plan member from the payer
perspective. A generalized linear model was used to evaluate patient or prescription
level variables that were associated with PMPM spending. Each patient included had
least one paid claim for an AAP during 2015. Patients with multiple claims in a given
month had all claim costs for AAP medications totaled for each month, then the total
days exposed per patient were determined. Patients with multiple claims for AAP
medications were aggregated to one PMPM cost per month for analysis. PMPM was
calculated as the total cost per month divided by the total days exposed per month
multiplied by thirty days. Total days exposed to AAP therapy was determined by
summing up the days’ supply of all paid claims in a given month per patient. The
PMPM variable was assessed for normality using a histogram and measures of skew.
The distribution appeared to be non-normal, with a skewness 1.11 indicating a long
right skewed tail and kurtosis value 2.1.23–25 A modified park test was performed to
determine the distribution for the cost model.25,26 Test statistics revealed coefficient
near two (lambda=1.76), which provides evidence the outcome to be modeled as a
gamma distribution. A log-link with the gamma distribution fit better than other link
options (log-link AIC=69,436, identity link AIC=69,448, logit link AIC=120,939)
and was the model employed in the final analysis.26 All statistical tests were two-sided
and performed at a 0.05 significance level and conducted using SAS Enterprise Guide
Version 7.1 (Cary, North Carolina, USA).
1.4 Results
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Table 1 provides overall mental health diagnoses of the original pediatric
cohort from 2015 prior to exclusion criteria, regardless of AAP medication therapy
presence. In the original patient database of pediatric patients in 2015, 87,503
pediatric patients had a mental health diagnosis of interest in a medical recording
during 2015. Before exclusion criteria were applied, 23% (20,732) of patients had a
diagnosis of Disruptive or Aggressive Behavior (DAB) Disorders, 14% (11,870) had a
diagnosis of Anxiety Disorders and 13% (11,611) had a diagnosis of Developmental
Disorders. Of the entire original pediatric cohort, 0.3% (210) of patients had a
diagnosis of six mental health diagnostic categories documented at a medical visit
claim during 2015. This population included 71,630 children with mental health
diagnoses of interest recorded in their medical claims in 2015 and continuous
eligibility for all of 2015. The mean age of the entire study population was 11.7
(standard deviation [SD]=4.1) years. Of the entire population, 63% were male (P
value <0.001). A total of 4,833 (6.8%; 95% CI=6.6, 6.9) patients received at least one
paid claim for an AAP medication in 2015. The prevalence of atypical antipsychotic
medication use was 67.5 per 1000 pediatric patients with mental health diagnosis of
interest.
We found that 1,378 (29%) of the 4,833 pediatric patients receiving AAP
medication therapy did not have a psychiatric diagnosis of interest at the associated
medical appointment (+ 60 days around AAP claim) during the study period (Table
2). In patients receiving an AAP paid claim, across the entire study period, the leading
diagnostic category present was 1336 children with Mood disorders (28%). Children
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with Disruptive or Aggressive Behavior (DAB) Disorders were next frequent with 842
(17%) children.
Several patient characteristics varied between those who received AAP
medications and those who did not (Table 2). Patients receiving AAP medications
were on average 2.1 years older than those receiving no AAP medication therapy.
Adolescents (age 13-17 years) received the most paid claims for AAP therapy (69%)
compared to children aged 6-12 years (30%) and 2-5 years (1%) (P value<0.001). The
distribution of region was comparable between the two groups. Concomitant
medication therapy with stimulant, antiepileptic, antidepressant and anxiolytic
medications was significantly different between the two groups. Children receiving
AAP medication therapy had increased rates of concomitant use of stimulants (9% vs
8%, P value<0.001)), antiepileptics (2% vs. 1%, P value<0.001), antidepressants (7%
vs. 4%, P value <0.001)) and anxiolytics (4% vs. 1%, P value<0.001) when compared
to children receiving no AAP medication therapy. Category of mental health
diagnosis of interest was significantly different between the patients receiving AAP
medication therapy and those that did not, with most patients in both groups having no
associated mental health diagnosis at most recent medical visit or associated with AAP
medication paid claim. Significantly more pediatric patients reported an anxiety
disorder as primary mental health diagnosis in the AAP medication group than in the
no AAP therapy group (12% vs. 6%, P value <0.001). Similarly, in pediatric patients
receiving AAP therapy, mood disorders were reported as the primary mental health
diagnosis (28% vs. 3%, P value <0.001) in significantly more cases, than in patients
with no AAP therapy. The prevalence of AAP use compared across patient
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characteristics is displayed below in Figure 2. This figure presents the prevalence of
characteristics in children with mental health diagnoses of interest, prescribed AAP
medication therapy among the entire study population of children included in the
analysis (N =71,630). The number of patients from the study cohort with that given
characteristic that are included in the denominator, are listed at the top of the column.
All patients included in this figure had a mental health diagnosis of interest during
2015, continuous eligibility during the study period and a medical visit associated with
a paid AAP claim or medical visit available for analysis.
Results from the unadjusted and adjusted logistic regression models are
displayed in Table 3. In the unadjusted model, several patient characteristics were
found to have significant differences in AAP prescribing among children with mental
health diagnoses of interest. Female children had 20% increased odds of being
prescribed AAPs than male children (odds ratio (OR) = 1.2; 95% confidence interval
(CI) = 1.1, 1.2). Children of an older age were 20% more likely (OR=1.2; 95%
CI=1.1, 1.2) to have a paid claim for AAPs. In the unadjusted model, children aged 612 years of age were 9.8 times more likely to be prescribed AAPs than children aged
2-5 years (OR=9.8; 95% CI=7.2, 13). Adolescents (ages 13-17) were 19 times more
likely to have a paid claim for AAP therapy (OR=19.0; 95% CI=14.0, 26.0). Patients
in the Midwest (OR=1.3; 95% CI=1.1, 1.4) and the South (OR=1.2; CI=1.1, 1.3)
regions of the US were significantly more likely to receive AAP therapy, compared to
subjects in the Northeast region. Patients with a documented Mood Disorder
diagnosis were 5 times more likely to receive an AAP paid claim (OR=23.0; CI=4.6,
5.8), compared to those with psychotic disorders as the primary mental health
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diagnosis. Patients with a documented mental health disorder in the “Other” category
were 2.8 times more likely to be prescribed AAPs (OR=2.8; 95% CI=2.2, 3.5)
compared to patients with a Psychotic Disorder documented. Patients with
documented Anxiety Disorder were 20% increased odds of having an AAP paid claim
(OR=1.2; 95% CI=1.1, 1.4) compared to children with documented psychotic
disorders. If the patient’s primary mental health diagnosis was for an DAB or
Developmental Disorder, the pediatric patient had 30% increased odds of having an
AAP paid claim (OR=1.3; 95% CI=1.1, 1.4), (OR=1.3; 95% CI=1.1, 1.6), compared to
patients with a Psychotic Disorder documented.
Concomitant use of several relevant medication classes was evaluated for
significance as predictors of receiving AAP medication therapy. In the unadjusted
model, a paid claim for stimulant medication during 2015 indicated 20% increased
odds of receiving AAP medication therapy (OR=1.2; 95% CI=1.1, 1.3). Concomitant
use of antidepressants in 2015 predicted 60% increased odds of being prescribed AAP
therapy (OR=1.6; 95% CI=1.4, 1.8). The use of antiepileptic medications in pediatric
patients with mental health diagnoses predicted they were 4 times more likely to be
prescribed an AAP medication (OR=4.0; 95% CI=3.2, 5.1). Patients with a paid claim
for anxiolytic medication in 2015 were 2.8 times more likely to also receive an AAP
medication (OR=2.8; 95% CI=2.4, 3.3) during study period. Provider specialty was
also evaluated as a clinically relevant predictor of AAP medication use. Patients seen
by a specialty provider (psychiatrist) had 5 times the increased odds of receiving an
AAP medication compared to patients seen by a primary care provider (OR=5.0; 95%
CI=4.5, 5.3). Similarly, pediatric patients with a mental health disorder seen by a
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specialist had 13 times increased odds of receiving a paid claim for AAP therapy than
patients seen by a non-physician mental health provider (OR=12.5; 95% CI=11.0,
14.0).
In the adjusted final model, female pediatric patients with mental health
diagnoses of interest had 11% decreased odds (adjusted odds ratio (aOR)=0.89; 95%
CI=0.83, 0.95) of having a paid claim for AAP medication therapy. In the final
model, age was a significant predictor in the prescribing of AAP medication, with a
one-year increase in age having an associated 10% increased odds of receiving a paid
claim for an AAP (aOR=1.1; 95%CI=1.0, 1.1). After adjusting for other patient and
clinical characteristics, children 6-12 years of age were 10 times more likely than
younger children to be prescribed AAP medication therapy, (aOR=10.3; 95% CI=7.5,
14.1). Adolescent patients with a mental health diagnosis of interest were 16 times
more likely to receive AAP medication therapy, when compared to children ages 2-5
years (aOR=16.7; 95% CI= 12.2, 22.9). In the final model, patients with a mood
disorder were 2 times more likely to receive an AAP medication, compared to patients
with a documented Psychotic Disorder (aOR=2.2; 95% CI=2.0, 2.6). Also, patients
with documented Developmental (aOR=1.4; 95% CI=1.2, 1.7) had a 40% increased
odds and patients with documented Other Disorders (aOR=1.6; 95% CI=1.2, 2.0) had
60% increased odds of receiving an AAP, compared to pediatric patients with
documented Psychotic Disorders. Patients with a documented Anxiety Disorder had
37% decreased odds of receiving a paid claim for an AAP (aOR=0.63; 95% CI=0.55,
0.73) compared to patients with a documented Psychotic Disorder. In the adjusted
model, patients with DAB Disorders had 29% decreased odds of having a paid claim
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for an AAP (aOR=0.71; 95% CI=0.62, 0.82) compared to patients with a documented
Psychotic Disorder. Finally, adjusting for other covariates, patients with no mental
health disorder documented had 80% decreased odds of receiving a paid claim for an
AAP (aOR=0.20; 95% CI=0.18, 0.23) compared to a documented Psychotic Disorder.
Once adjusting for other covariates, pediatric patients with concomitant use of
stimulant medications had 48% decreased odds of being prescribed AAP medication
therapy (aOR=0.52; 95% CI=0.46, 0.58) in the final adjusted model. Similarly,
patients with concomitant antidepressant use had 55% decreased odds of being
prescribed AAP medications (aOR=0.45; 95% CI=0.39, 0.50). After adjusting for
other covariates, the use of antiepileptic medications during 2015 predicted 50%
increased odds of having a paid claim for AAP medication during the study period
(aOR=1.5; 95% CI=1.2, 2.0). After adjusting for other covariates, pediatric patients
with mental health disorders demonstrating anxiolytic use during the study period no
longer had a significant effect on likelihood of receiving an AAP paid claims.
Overall, demonstrated use of other psychotropic medication classes were significant
predictors in the prescribing or not prescribing of AAP medication therapy. Of note,
in the adjusted model, several variable associations changed directions when adjusted
for other covariates. In the adjusted model, female gender, use of stimulants and use
of antidepressants were associated with a reduced risk of AAP use, which was a
change from an increased risk in their respective univariate models. By adding one
variable to the model at time, we determined that these estimates changed direction
after adjustment for age group. This indicates that the age group of the patient at time
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of paid claim demonstrates some unmeasured confounding affecting the other
covariates, that is independent of the direct interaction of the variables.
In the adjusted model, prescriber specialty was a significant predictor for AAP
prescribing. Patients seen by a specialty provider had 2.5 times the increased odds of
receiving a paid claim for AAP medication than patients seen by a primary care
provider (aOR=2.5; 95% CI=2.3, 2.7). Patients seen by a specialist had 5 times the
increased odds of receiving an AAP medication paid claim than children seen by a
non-physician mental health professional (psychiatric nurse practitioner, physician
assistant) (aOR= 5.0; 95% CI=4.5, 5.6). After adjusting for other patient
characteristics, region was no longer a statistically significant predictor of AAP
prescribing in the final model.
Cost Model for AAP Medications Use in Pediatric Patients
The total 2015 annual expenditure for AAP prescriptions in the pediatric
population with mental health conditions was estimated at $12,487,066.71, in a large
US private payer. This expenditure represented 35,311 paid claims for AAP
medication therapy and 5,253 unique patients over the study period. This
corresponded to an average spending of $1.04 million per month for AAP medication
in pediatric patients with mental health conditions for the private insurance plan. The
average and median per-member-per-month (PMPM) costs of AAP medication
therapy was $311.58 (standard deviation [SD]=$327.16) and $169.06 (quartile 1 to
quartile 3 [Q1,Q3] = $$19.62, $556.32), respectively. The 12-month average AAP
medication cost per patient was $3738.96 (SD=$3925.92).
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The median cost per paid claim in 2015 is displayed by medication in Table 4.
Generic risperidone was the most commonly prescribed atypical antipsychotic
medication (25%) followed by generic aripiprazole (22%) and name brand Abilify®
(20.0%). The median cost of a paid claim for generic risperidone was $21.04
(Q1=$12.39, Q3=$31.55) per claim, representing almost the lowest cost per claim of
all the AAP agents. The median cost of a paid claim for name brand aripiprazole was
$978.86 (Q1=$978.86, Q3=$978.86) per claim, representing the highest cost per paid
claim compared with all other available AAP agents.
The cost data was then analyzed using a generalized linear model (GLM) to
determine any covariates that were a significant predictor of PMPM costs. Table 5
presents the results of the log-gamma regression of the per-member per-month
(PMPM) costs during the 12-month study period adjusted for patient demographics.
Using a gamma regression model with an identity link function, age group, gender,
mental health diagnostic category and provider specialty were statistically significant
predictors of total annual expenditure for AAP medication therapy. Children aged 612 years had overall adjusted mean spending for AAPs that was $90.22 (95% CI=$14.40, $155.45) higher than patients aged 2-5 years. This corresponds with a PMPM
that was 50% (adjusted odds ratio (aOR)=1.5; 95% CI=0.97, 2.1) higher than children
aged 2-5 years. Adolescents aged 13-17 years had overall adjusted mean spending for
AAPs that was $116.62 (95% CI=$12.48, $180.63) higher than patients aged 2-5
years. This corresponds with PMPM costs that were 60% higher (aOR=1.6, 95%
CI=1.1; 2.3) than children aged 2-5 years. Older patients often require higher doses of
medication therapy or more frequent administration and these dosing regimens often
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cost more. Female subjects had overall adjusted mean spending for AAPs that was
$30.69 (95% CI= $7.36, $54.67) higher than male subjects. Female gender
represented a PMPM cost that was 10% (aOR=1.1;95% CI=1.0, 1.2) higher than male
subjects. The adjusted difference in mean spending for AAPs between subjects from
different US regions was only significant comparing patients located in the South to
the Northeast. Pediatric patients located in the South region of the US had overall
adjusted mean spending on AAPs that was $38.89 (95% CI= $0.78, $73.93) higher
than patients in the Northeast US. This represented overall PMPM costs that were
10% (aOR=1.1; 95%CI=1.0, 1.3) higher than children located in the Northeast region.
1.5 Discussion
In privately-insured children and adolescents, the prevalence of atypical
antipsychotic medication therapy was 67.5 per 1000 patients (6.75%; 95% CI=6.6%,
6.9%) with a mental health diagnosis of interest present in 2015. In our study, gender
was associated with differences in prescribing AAP therapy, which aligned with
previous research in private- and publicly-insured children.11,15,27 These previous
studies found that patients of male gender had increased odds of receiving AAP
medication therapy. Our study found similar increased odds in male patients. The
children receiving AAP therapy were significantly older (13.6 vs. 11.8 years) and
older age was an important predictor of a patient receiving AAP therapy.
In our analysis, the 2015 prevalence of atypical antipsychotic use was higher
than determined in previously studied research of privately-insured children and
adolescents across the US.15 Previous studies have found that publicly-insured youth
have consistently lower AAP prevalence to that found in our study, at 1.9% in 2005
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and 1.7% in 2010.11 Since 2005, the AAP medication therapy options have doubled,
as AAP medication approvals have increased dramatically in the US. Furthermore,
previous studies in publicly insured population included all children, not only children
with mental health diagnoses present in medical records for their analysis. 8,11,19
Including all children in the analysis could increase the population that is considered at
risk for AAP medication use, leading to a possible underestimation of the proportion
of study participants that received AAP medication therapy. These differences in study
population could explain some of these observed differences. Private insurance payers
have different formulary practices than public payer systems. Formulary approval and
reimbursement practices could change the utilization and diversity of a medication
class and represent the difference between our study and the results from studies
analyzing publicly funded patients. Combination therapy with multiple AAP
medications or therapy switching was not examined in this analysis. Combination
therapy or medication switching is common in mental health treatment
recommendations and represents a future direction that should be explored. Future
research should also examine overlapping medication classes with AAP therapy or
switching therapy to AAP as a significant factor in AAP medication use in pediatric
patient with mental health diagnoses.
Our study found that 29% of pediatric patients treated with an atypical
antipsychotic have no mental health diagnosis in an associated claim for medical visit
within 60 days of the paid prescription claim. Figure 2 shows the overall distribution
of mental health diagnosis in the pediatric patients that supported their inclusion in the
original study cohort. Among pediatric patients with a mental health diagnosis
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present, Developmental disorders (13%), Anxiety Disorders (14%) and Disruptive or
Aggressive Behavior (DAB) disorders (23%) were the leading diagnoses associated
with AAP medication therapy. In the original database of pediatric patients with
mental health diagnoses during calendar year 2015 (Figure 1), 0.3% (210 patients) of
pediatric patients had all six mental health diagnostic categories present at a medical
visit during the study period. The absences of mental health diagnoses in the
associated medical visit around the paid claim for AAP medication therapy could be
explained by the lack of coding in the medical visit for continued medication treatment
by the visit provider. Lohr et al. analyzed AAP use in Kentucky Medicaid patients and
found that 72% of subjects analyzed were missing a diagnostic code associated with
paid claim and this issue was only resolved after 2006 once Medicaid rules required an
appropriate code before paid claim would be fulfilled.10 Other previous trend studies
in public- and privately-insured pediatric patients categorized missing diagnoses as
“other” or excluded patients with no diagnosis available completely.8,28 The rate of
missing mental health diagnosis found in our study was lower than previously
published literature. A 2015 study found no mental health diagnosis present at an
associated medication visit in 60% of pediatric patients treated with AAPs.12 Previous
research also found that in 75% of cases, all children with MH diagnoses of interest
treated with AAP medications has multiple psychiatric diagnoses.15 Similarly, we
found that in the original cohort, 44% of children had multiple mental health
diagnoses present during the study period.
We found that specialty providers were the leading prescribers (41%)
associated with paid claims for AAP therapy. Olfson et al.12 noted that specialists
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were the provider associated with AAP therapy in approximately 69% of paid claims
in 2010. The differences in associated prescriber characteristics could be related to
coding differences between private insurers and their claims process. Prescribing
physician requirements can differ between private and public payers. Formulary
requirements for certain payers require specialist prescribing for certain populations or
medication classes that may not be required of practices in our privatively-insured
population.
Concomitant medication therapy was a significant predictor of a pediatric
patient receiving AAP therapy. Use of stimulant and anxiolytic medications reduced
the likelihood of a patient receiving a fill of an AAP medication in 2015. Sikirica et
al. previously explored ADHD patients receiving stimulant therapy and the likelihood
of receiving AAP medication therapy.12 Their study identified 8.3% of stimulant
treated children receiving an AAP in the 12-month study period.13 Our study found a
similar rate of concomitant use of stimulants with AAP medication therapy. Olfson et
al. explored the overall rate of concomitant use of anxiolytics and antidepressants with
antipsychotic medication treatment.9 Their study found much higher rates of
antidepressant use (33.7%) and anxiolytic use (9.7%) in patients on AAP medication
therapy, than was identified in our current study. This previous analysis was based on
medical office visits documenting the medication of interest and not based on
individual paid claims for the relevant medication class. This methodology could
explain the increased rates of concomitant use found in their study compared to results
presented here. In this previous study, it is unclear if the patient was receiving the
medication or the provider only discussed the medication therapy during the office
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visit. The use of antidepressant and stimulant medications when analyzed alone,
seemed to be a significant predictor of AAP use. However, in the adjusted model
concomitant use of these two classes of medications showed lower odds of predicting
use of AAP medications. This might indicate that some confounding is present and
the other significant variables (age, gender, region, mental health diagnosis, provider
specialty) are confounders for concomitant use of antidepressants and stimulants and
their effect on AAP prescribing.
Our study is one of the first to describe the 12-month average medication cost
of AAP therapy in the privately-insured pediatric patient population. The total 12month cost burden for 35,311 paid claims for AAP medication therapy was $12.5
million in 2015, representing 5,253 unique patients over the study period. The
average per-member per-month (PMPM) cost for the entire study population was
$311.58. This study found that aripiprazole (name brand and generic) was the most
commonly prescribed AAP medication in privately insured youth, with 44% of paid
claims. Olfson and collegues12 described risperidone as the most common AAP agent
used in privately insured youth in 2010. This difference in choice of agents is most
likely related to the pediatric indications granted by the FDA for aripiprazole and its
dosage forms in 2009 and the availability of a generic formulation in 2015.29
In 2015, we estimated that $12.5 million was spent on atypical antipsychotic
medication therapy among this privately-insured pediatric population. In a similar
study of children enrolled in Florida Medicaid, researchers found that in Fiscal Year
2005 (FY2005) , $151 million was spent on AAP medication therapy. 30 This drastic
difference compared to our study findings can most likely be explained by the peak
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utilization that was seen for AAP medication therapy in 2005 and lack of generic
formulations available on the US market. Their study adjusted dollar spending
amounts to align with the medical care component of the consumer price index for the
region during the FY2005.30 Our study took direct costs paid by the payer from
prescription claims data. Most of the available cost research focuses on publiclyinsured children and our study is one of the first to explore the direct medication costs
to a private, national payer. In 2004, the FDA issued advisory committee findings that
recommended more conservative use of atypical antipsychotics in children and Pamer
et. al examined a corresponding decrease in AAP medication use.28,31 This research
group observed a decline in AAP medication prescribing, but this decline did not
achieve statistical significance nor did they examine overall spending or changes in
average cost.31 In 2016, Wang et al. performed a time-trend analysis examining AAP
medication prescribing before and after supplemental pediatric indications being
granted by the FDA. They found no statistically significant changes in AAP
medication prescribing with the additional approved pediatric indications.28 These
studies provide limited evidence that the FDA medication safety alert and other
prescribing decisions might have altered antipsychotic medication prescribing. Future
studies that compare time trend utilization data against major clinical guideline
recommendations or new FDA indications for AAP medications in larger population
could provide stronger evidence of these influence of these administrative actions on
prescribing habits.
1.6 Limitations
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The analysis was conducted using insurance claims data; therefore, limited
clinical information was available for patients that were included in the final analyses.
Clinical information from claims data is limited to available medical documentation
presented in the visit record as recorded by the documenting provider. Physical
assessment information about the patient and laboratory information was limited and
not included in the analysis. A mental health diagnosis of interest was not present in
the medical visits associated with index AAP paid claim in 29% of the patients
receiving AAP medication therapy. Prior studies have demonstrated the validity of
ICD-9 codes for accurately representing a mental health diagnosis in the medical
record.21,22 However, other prevalence studies have found a similar rate of an absence
mental health diagnosis associated with medication use. The window around the
index claim for AAP therapy was expanded from +/- 30 days to +/- 60 days; however,
this did not improve the capturing of diagnostic information from medical visits. This
rate of incomplete mental health diagnosis documentation could make it difficult to
interpret the proper clinical indication for AAP medication use. Miscoding in the
practical setting could lead to variations in the results and make analysis by clinical
disorder difficult to interpret. Furthermore, the observed study period may not have
captured the incident mental health event for a patient, so we could be observing
patients well after their initial diagnosis. The cost portion of this analysis only
discussed the direct medication costs to the private healthcare plan and did not address
other economic costs, such as utilization of other treatment resources, cost to
caregivers and parents and lost school or work time. Finally, the prevalence and cost
analyses both use the paid claim as the basis for evaluation. For concomitant
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medication therapy and its significance as a predictive variable, only paid claims
during study period was examined.
1.7 Conclusion
The prevalence of using atypical antipsychotic medications in pediatric patients
with mental health disorders is significant in the privately insured population. The
prevalence in the privately insured population was 6.75% (CI=6.6%, 6.9%) or 67.4 per
1000 children with mental health disorders in 2015. The total yearly spending by the
private payer for atypical antipsychotic medications in pediatric patients was $12.5
million dollars in 2015. This represented an average per-member per-month cost of
$311.58 for atypical antipsychotic medication therapy in pediatric patients with mental
health diagnoses of interest. Individual costs vary greatly by AAP medication and
further costs studies are warranted to determine the potential economic impact to a
specific private payer. This study represents the most recent calendar year available
for analysis.
Overlap or switching of therapy to or from AAP medication therapy was not
examined but could be evaluated in future studies. Combination therapy with other
AAP medications or other psychotropic medications is a common clinical practice and
the possible impact on AAP utilization should be examined. Validation studies of the
ICD-9 codes use for mental health diagnoses in the outpatient medical record warrant
additional validation studies. Validation studies available are specific for claims data
research in adults with mental health disorders. Providers may believe a stigma exists
in documenting mental health conditions in the pediatric population and diagnostic
code analysis may not be as reliable. These studies could provide additional insight in
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to the use of diagnostic codes and the predictive value in mental health epidemiologic
studies. Further studies about updated utilization and spending are needed to examine
how more recent FDA decisions and safety alerts may have altered AAP prescribing
and medication class utilization.
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Figure 1: Selection of Patients for Analyses of Prevalence of Atypical Antipsychotic Medication
Utilization and Cost of Atypical Antipsychotic Medication Therapy in Pediatric Patients (2 to 17
years) (2015).
(Optum Clinformatics ® Data Mart; OPTUMInsight, Eden Prairie, MN)

898,293 All patients with mental
health diagnosis of interest in
2015

810,790 Excluded adult
patients (age > 18 years) with
mental health diagnoses of
interest in 2015

87,503 Pediatric patients (age 217 years) with at least one
mental health diagnosis of
interest (2015)
15,873 patients excluded
due to non-continuous
eligibility during study
period
71,630 Pediatric patients with
continuous eligibility for all of
2015
•
study population for
prevalence of AAP
medication use

5,253 Individual pediatric
patients with at least one paid
claim for AAP medication
during 2015

66,797 Pediatric patients with
no paid claim for AAP
medication therapy in 2015
and available medical records

4,833 Individual patients
with paid claim for AAP and
available medical records
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35,311 Paid claims for
AAPs in eligible children
in 2015
•
study population
for cost study

Table 1. Distribution of Mental Health Diagnoses in all Pediatric Patients (2 to17 years)
Available in Study Cohort during 2015. *
(Optum Clinformatics ® Data Mart; OPTUMInsight, Eden Prairie, MN)

Primary MH Diagnosis of Interest

All children (N, %) with
Mental Health Diagnosis
(N= 87,503)
Disruptive or Aggressive Behavior Disorder
20732 (23)
Anxiety Disorder
11870 (14)
Developmental Disorder
11611 (13)
Three MH Disorders present
10192 (12)
Anxiety and Secondary MH Disorder
10187 (12)
Developmental Disorder with Secondary MH Disorder
6846 (8)
Disruptive and Aggressive Behavior with Secondary MH Disorder
2935 (3)
Mood and secondary MH Disorder
4087 (5)
Four MH Disorders Present
2929 (3)
Mood Disorder
2798 (3)
Psychotic Disorder
1315 (2)
Other Mental Health Disorder
1181 (1)
Five Mental Health Disorders Present
454 (0.5)
Six Mental Health Disorders Present
210 (0.3)
Psychotic Disorder with Secondary MH Disorder
156(0.2)
*No exclusion criteria applied. All pediatric patients with at least one MH diagnosis included in original cohort.
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Table 2. Demographic and Clinical Characteristics of Privately-Insured, US Children (2 to 17
years) with Mental Health Diagnoses of Interest during 2015 by AAP status (N =71,630)
(Optum Clinformatics ® Data Mart; OptumInsight, Eden Prairie, MN)

Children with an
AAP paid claim
(N=4,833)
13.7 (3.0)

Children with no
AAP Treatment
(N=66,797)
11.6 (4.2)

41 (0.9)
1439 (29.8)

7525 (11.3)
26921 (37.6)

13-17 years (adolescents)

3353 (69.4)

32351 (48.4)

Patient Gender, n (%)
Male

2891 (59.8)

42166 (63.1)

Female

1942 (40.2)

24631(36.9)

Patient Age, Years, Mean+ SD
Age Group (years) n(%)
2-5 years (pre-school)
6-12 years

P value*

<0.001
<0.001

<0.001

Patient Region, n (%)
<0.001
Northeast
523 (10.8)
8300 (12.4)
Midwest
1609 (33.3)
20278 (30.4)
South
1953 (40.4)
26763 (40.1)
West
748 (15.5)
11456 (17.2)
MH Diagnosis Category, n (%)
<0.001
Anxiety Disorder
571 (11.8)
3884 (5.8)
Mood Disorders
1336 (27.6)
2183 (3.3)
Disruptive or Aggressive Behavior 842 (17.4)
5581 (8.4)
Disorders
Developmental Disorders
169 (3.5)
1072 (1.6)
Psychotic Disorders
417 (8.6)
3510 (5.3)
Other MH Disorders
120 (2.5)
366 (0.6)
No MH Diagnosis Present
1378 (28.5)
50201 (75)
Use of Antiepileptics, n (%)
<0.001
Yes
92 (1.9)
319 (0.5)
No
4741 (98.1)
66478 (99.5)
Use of Antidepressants, n (%)
<0.001
Y
312 (6.5)
2817 (4.2)
N
4521 (93.5)
63980 (95.8)
Use of Anxiolytics, n (%)
<0.001
Y
181 (3.8)
922 (1.4)
N
4652 (96.2)
65875 (98.6)
Use of Stimulants, n (%)
<0.001
Y
444 (9.2)
5174 (7.8)
N
4389 (90.8)
61623 (92.2)
Provider Specialty, n (%)
<0.001
Acute Care Hospital
154 (3.2)
4332 (6.5)
Mental Health Professional (non578 (11.9)
3198 (4.8)
physician)
Outpatient Facility
209 (4.3)
2361 (3.5)
Primary Care Provider
810 (16.8)
14843(22.2)
Specialist
2003 (41.4)
7416 (11.1)
Therapy Provider (Social Worker,
384 (8.0)
3026 (4.5)
Psychologist)
Other Non-Physician Provider
695 (14.4)
31621 (47.3)
*comparisons in baseline characteristics between children receiving AAPs and those that did not
during study period using Chi-Squared tests or t-tests as appropriate.
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Figure 2. Prevalence of Privately-Insured Children (2 to 17 years) with Mental Health Disorders
in the US Receiving AAP Medication Therapy in 2015 by Patient and Clinical Characteristics (n
=71,630).*

*Number of children present in study cohort with given covariate listed at top of column (denominator)
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Table 3. Unadjusted and Adjusted Odds Ratios (ORs) with 95% Confidence Intervals (CIs)
Based on a Logistic Regression Model for Patient and Clinical Factors Associated with Atypical
Antipsychotic Medication Prescribing among US Privately-Insured Pediatric Patients (2 to 17
years) in 2015 (N=4,833).

Patient Age
Age Group (years)
2-5 years
6-12 years
13-17 years (adolescents)
Gender
Female
Male
Region
Midwest
South
West
Northeast
Mental Health Diagnosis
Anxiety Disorders
Mood Disorders
Disruptive or Aggressive Behavior
Disorders (DAB)
Developmental Disorders
Psychotic Disorders
Other MH Disorders
No MH Diagnosis Present
Provider Category
Acute Care Hospital
Mental Health Professional (nonphysician)
Outpatient Facility
Primary Care Provider
Specialty Provider
Therapy Provider (Social Worker,
Psychologist)
Other non-physician provider
Use of Stimulants
Yes
No
Use of Anxiolytics
Yes
No
Use of Antidepressants
Yes
No
Use of Antiepileptics
Yes
No

Unadjusted
ORs (95% CIs)
P value
1.2 (1.1, 1.2)
<0.001
<0.001
Reference
9.80 (7.20, 13.0)
19.0 (14.0, 26.0)
<0.001
1.20 (1.10, 1.2)
Reference
<0.001
1.3 (1.1, 1.4)
1.2 (1.1, 1.3)
1.0 (0.9, 1.2)
Reference
<0.001
1.2 (1.1, 1.4)
5.2 (4.6, 5.8)
1.3 (1.1, 1.4)

Adjusted*
ORs (95% CIs)
P value
1.1 (1.1, 1.1)
<0.001
<0.001

1.3 (1.1, 1.6)
Reference
2.8 (2.2, 3.5)
0.23 (0.21, 0.26)

1.4 (1.2, 1.7)

10.3 (7.5, 14.1)
16.7 (12.2, 22.9)
<0.001
0.89 (0.83, 0.95)
0.075
1.1 (1.0, 1.3)
1.1 (1.0, 1.3)
1.0 (0.9, 1.1)
<0.001
0.63 (0.55, 0.73)
2.2 (2.0, 2.6)
0.71 (0.62, 0.82)

1.6 (1.2, 2.0)
0.20 (0.18, 0.23)
<0.001

<0.001

0.13 (0.11, 0.16)
0.67 (0.61, 0.74)

0.19 (0.16, 0.23)
0.42 (0.38, 0.47)

0.33 (0.28, 0.38)
0.20 (0.19, 0.22)
Reference
0.47 (0.42, 0.53)

0.68 (0.58, 0.81)
0.40 (0.36, 0.43)

0.08 (0.07, 0.09)

0.20 (0.2, 0.2)

0.41 (0.4, 0.5)

1.2 (1.1, 1.3)
Reference

0.003

0.52 (0.5, 0.6)

<0.001

2.8 (2.4, 3.3)
Reference

<0.001

1.2 (1.0, 1.4)

0.12

1.6 (1.4, 1.8)
Reference

<0.001

0.45 (0.4, 0.5)

<0.001

4.0 (3.2, 5.1)
Reference

<0.001

1.5 (1.2, 2.0)

0.002

*adjusted for the following covariates at baseline: age group, gender, US region, Mental Health
Diagnosis, Provider Category, Concomitant use of stimulants, anxiolytics, antidepressants and
antiepileptics.
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Table 4. Median Costs (US Dollars) per paid claim and Total Spending for Atypical Antipsychotic
Therapy for Privately-Insured, US Children (2 to 17 years) with Mental Health Disorders during
2015 (N=5,253 patients with 35,311 paid claims).
Medication Name
Number of Paid Median (Q1, Q3) *
Total Spending in
Claims (%)
2015, $ (% of yearly
total)
Abilify (name brand)
7,094 (20)
978.86 (978.86, 978.86)
5,621,429.06 (45)
Aripiprazole (generic)
7,664 (22)
531.23 (519.79, 668.89)
4,614,370.15 (37)
Clozapine
307 (0.9)
46.57 (23.93, 121.66)
24,095.85 (0.2)
Fanapt
84 (0.2)
635.67 (317.84, 635.67)
41,647.13 (0.3)
Geodon (name brand)
34 (0.1)
635.94 (476.96, 771.74)
19,814.11 (0.2)
Invega (name brand)
406 (1.1)
665.48 (665.48, 998.22)
334,147.95 (2.7)
Latuda
1123 (3.2)
638.68 (638.68, 638.68)
758,792.30 (6.1)
Olanzapine (generic)
1624 (4.6)
23.89 (19.60, 33.16)
48,637.88 (0.4)
Olanzapine ODT
134 (0.4)
211.74 (112.06, 420.31)
38,568.81 (0.3)
Palperidone ER
79 (0.2)
641.99 (610.96, 800.97)
55,694.41 (0.5)
Quetiapine Fumarate
5343 (15)
19.50 (9.55, 32.37)
148,893.23 (1.2)
(generic)
Risperdal (name brand)
42 (0.1)
613.91 (511.59, 1367.94) 31,340.74 (0.3)
Risperdal M-TAB
11 (0.03)
704.93 (704.93, 704.93)
7,754.23 (0.1)
Risperidone (generic)
8814 (25)
21.04 (12.39, 31.55)
241,841.20 (1.9)
Risperidone ODT (generic)
229 (0.7)
182.15 (95.89, 335.34)
51,671.77 (0.4)
Saphris
309 (0.9)
345.69 (345.69, 691.37)
155,686.00 (1.3)
Ziprasidone HCL (generic)
2010 (5.7)
96.92 (44.55, 197.64)
290,796.45 (2.3)
Zyprexa (brand name)
4 (0.01)
471.36 (471.36, 471.36)
1885.44 (0.02)
Total Yearly Spending for AAP Medication Therapy
$12,487,066.71
*Quartile 1 (Q1) and Quartile 3(Q3) representing first and third quartiles for median value
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Table 5. Cost Ratios and Mean Cost Differences (US Dollars) with 95% Confidence Intervals
(CIs) Based on a Gamma Generalized Linear Regression Model of Per-Member Per-Month
(PMPM) Costs for AAP Medication Therapy in Pediatric Patients (2 to 17 years) with Mental
Health Diagnoses of Interest in United States, 2015 (N=5,253 patients with 35,311 paid claims)
Unadjusted Modelb

Independent
Variable
Mean Cost
Difference, $a,
(95% CI)
173.01 (102.52, 280.59)

Cost Ratio

95% CIs

Adjusted Modelb,c
P-value

Cost
Ratio

95% CIs

Intercept
Age Group
2-5 years
Reference
Reference
Reference
6-12 years
90.22 (-14.40, 155.45)
5.8
5.7, 5.8
<0.001
1.5
0.97, 2.1
13-17 years
116.62 (12.48, 180.63) 5.3
4.9, 5.7
<0.001
1.6
1.1, 2.3
Gender
Male
Reference
Reference
Reference
Female
30.69 (7.36, 54.67)
5.8
5.7, 5.9
<0.001
1.1
1.0, 1.2
Region
Northeast
Reference
Reference
Reference
Midwest
12.45 (-26.00, 47.97)
5.7
5.7, 5.8
<0.001
1.0
0.92, 1.2
South
38.89 (0.78, 73.93)
5.8
5.7, 5.9
<0.001
1.1
1.0, 1.3
West
20.66 (-45.54, 95.96)
5.7
5.6, 5.8
<0.001
1.0
0.86, 1.1
a Unadjusted and adjusted mean costs per patient was estimated using the identity link function
bUnadjusted and Adjusted coefficients of gamma regression were estimated using the log link function and are
reported as a ratio of average per member per month (pmpm) costs.
cThe following covariates were adjusted for in the final model: age group, gender and US region.
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P-value

0.05
0.02

0.01

0.56
0.04
0.86
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2.1 Abstract
BACKGROUND: The overall trend of use for AAP in pediatric patients with mental
health disorders has increased over the last 20 years. From 1995 to 2002, multiple
studies demonstrated a 5-fold increase of antipsychotic use in pediatric and adolescent
patients in the United States.1–3 This treatment is often “off-label” or not for a specific
Food and Drug Administration (FDA)-approved condition in children or
adolescents.1,2,4,5 Furthermore, 20% of pediatric patients prescribed an atypical
antipsychotic medication had no FDA approved diagnosis associated with treatment.6
As of 2010, most of the trend studies focused on publicly-insured children, such as
Medicaid enrollees, with few studies evaluating large, privately-insured populations.
The available studies suggest a growing trend in atypical antipsychotic use in pediatric
patients, but only limited studies evaluated this medication class use in privatelyinsured patients.
OBJECTIVE: This study identified the trend in atypical antipsychotic medication
prescribing in pediatric patients from 2010 to 2015. It also determined the rate of offlabel prescribing by diagnosis of AAP medications in the same study population.
METHODS: An administrative dataset (Optum Clinformatics ® Data Mart;
OptumInsight, Eden Prairie, MN) containing prescription claims between 2010 and
2015 was examined for all children 2 to 17 years of age who had a documented paid
claim for an atypical antipsychotic medication. Patient demographic and clinical
characteristics were analyzed using descriptive statistics. A generalized estimating
equation (GEE) model with Poisson variance and a log-link was used to determine any
demographic or clinical characteristics that predicted atypical antipsychotic use. To
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characterize off-label diagnostic prescribing, a GEE model with a binomial variance
and a log-link was employed to evaluate patient and clinical factors as predictors of
off-label use in pediatric patients.
RESULTS: A total of 378,007 paid claims were evaluated, representing 40,750
individual patients aged 2 to 17 years old. The use of atypical antipsychotics within
the entire pediatric population increased over the study period from 0.19% in 2010 to
0.28% in 2015. The rate of AAP paid claims per year for pediatric patients slightly
increased with each calendar year: 57% in 2011, 63% in 2012, 79% in 2013, 73% in
2014. In 2015, pediatric patients had a 270% increase in the yearly rate of claim count
per year during the study period (Rate Ratio (RR)=2.7; 95% confidence interval (CI)
=2.6, 2.9), compared to 2010. Female patients had 10% reduction in the rate of paid
AAP claims, compared to males (RR=0.90; 95% CI=0.89, 0.92). Our study found that
both children 2-5 years old and children 6-12 years old had a 20% increase in the rate
of paid AAP claims over the study period, compared to older children 13-17 years old
(RR=1.2; 95% CI=1.1, 1.2; RR=1.2; 95% CI=1.1, 1.2).
Off-label prescribing by diagnosis of AAP medications represented 62% (95%
CI=62%, 63%) of the paid claims evaluated. Children 2-5 years old were 43% less
likely to be prescribed atypical antipsychotics for off-label diagnoses (adjusted odds
ratio (aOR)=0.57, 95% CI =0.37, 0.90) than children 13-17 years old. Children 6-12
years old were 10% less likely (aOR = 0.90; 95% CI=0.77, 1.0) than adolescents (age
13-17 years) to be prescribed atypical antipsychotics for off-label indications. Female
pediatric patients were 1.2 times more likely to be prescribed an AAP in an off-label
manner (aOR=1.2; 95%CI=1.1, 1.3) compared to male children.
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CONCLUSION: The use of atypical antipsychotic in children 2-17 years old
increased overall from 2010 to 2015. This increase could be attributed to more
atypical antipsychotic medications available in the US market. Over the study period,
the number of AAP agents approved by the FDA increased substantially, from 7
agents to 13 available on the US pharmaceutical market. The practice of off-label
prescribing by diagnosis is prevalent in the pediatric population, despite the lack of
formal indications for pediatric use in this medication class.
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2.2. Introduction
The overall trend of use for AAP in pediatric patients with mental health
disorders has increased over the last 20 years. From 1995 to 2002, multiple studies
demonstrated a 5-fold increase of antipsychotic use in pediatric and adolescent
patients in the United States.1–3 This increase was largely due to the increased
availability of atypical antipsychotics and the common misconception that atypical
antipsychotics demonstrated lower risk of serious adverse events.7,8 Cooper et al
examined antipsychotic mediation use in publicly-insured youth and found that 53%
of incident users were being treated for mood or behavior disorders, rather than
traditional psychiatric conditions.1,4,7,9 This treatment is often “off-label” or not for a
specific FDA-approved condition in children or adolescents.1,2,4,5 Furthermore, 20%
of pediatric patients prescribed an atypical antipsychotic medication had no FDA
approved diagnosis associated with treatment.6 The medications of interest and the
corresponding FDA approval are listed in Appendix B.10 As of 2010, most of the
trend studies focused on publicly-insured children, such as Medicaid enrollees, with
few studies including large, privately-insured populations. The available data suggests
a growing trend in atypical antipsychotic use in pediatric patients; however, there have
been few studies that evaluated this medication class use in privately-insured patients.
More data in privately-insured children is unavailable and evaluation of the trend
among privately-insured children has not been characterized nor compared to a
population of publicly-insured children.4,5,7,9,11 This study evaluated the overall
utilization of these medications among privately-insured pediatric patients and
discussed comparisons to publicly-insured children.
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Clinical and demographic characteristics of youth receiving atypical
antipsychotic medications are not fully understood. Available analyses of commercial
and Medicaid prescription claims indicated that AAP treatment was significantly more
common in boys than girls.5,9,12,13 According to several state Medicaid studies,
treatment of mood disorders, attention-deficit/hyperactivity disorder or disruptive and
aggressive behavior disorders accounted for the majority of antipsychotic use.4,5,14
One sample population of psychiatric outpatient visits found 77% of children had no
diagnosis of any psychotic disorder associated with AAP medication therapy.15 The
data for commercial or privately-insured patients is limited and there remains
uncertainty if the finding for publicly-insured children persists in the privatelyinsured population.
Utilization and medication costs can vary over time based on market changes.
Since 2007, there has been a doubling in the number of AAPs approved on the US
market with demonstrated use in the pediatric population.10 However, most available
measures of prevalent use are somewhat dated and based on data from before 2009.
The increasing off-label use of medications, including AAPs, has been criticized and
contested in legal cases, leading to changes in recommendations for such use by the
FDA in 2009. Studies highlighting the off-label use of AAPs in the elderly has drawn
criticism and concern, leading to Medicaid earning reimbursement for spending for
off-label prescribing.16,17 Policy makers anticipate similar off-label utilization in the
pediatric population. The proportion of prescriptions authorized for off-label use in
pediatric patients has not yet been evaluated in the privately-insured population.
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Prior research that indicated increased use of atypical antipsychotic medication
in children, coupled with the potential increase in off-label use, have led to public and
professional uncertainty regarding recommended treatment regimens. The goal of this
study was to evaluate annual trends in prevalent use of AAP medication over 6-year
period from 2010 to 2015 in a large, privately-insured pediatric population and
evaluate the appropriate use of AAPs for a given mental health diagnoses.
Appropriate use was determined by labeled FDA indications for AAP medication
referenced in the paid claim. We hypothesized that AAP medication utilization
increased over the 6-year available study period and off-label prescribing of AAP
medication represented the predominant use in pediatric patients.
2.3 Methods
This retrospective cohort study identified all paid prescription claims for AAP
medications used in pediatric patients from 2010 through 2015. For each calendar
year of the study period, patients were identified that were 2 to <18 years of age (as of
the start of the year) and filled at least 1 prescription for an AAP agent during the year.
We reported the number of patients who used any AAP overall and stratified by
specific AAP agents. The utilization of AAPs was quantified as the prevalence of
AAPs use; that is, the proportion of the pediatric population on AAPs during each
year. Incidence of AAP therapy was also evaluated at the first year of follow-up to
assess patients newly prescribed. All pediatric patients present for analysis in the
administrative database (Optum Clinformatics ® Data Mart; OptumInsight, Eden
Prairie, MN) were considered in the prevalence calculation.
Data Source and Study Design
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This retrospective longitudinal study used the commercial data set (Optum
Clinformatics ® Data Mart; OptumInsight, Eden Prairie, MN) from January 2010 to
December 2015. This data includes commercial health insurance claims (inpatient and
outpatient medical records, laboratory data, facility information, and outpatient
pharmacy) and enrollment data from large, private insurer across the United States.18
This dataset provides healthcare information on 36 million beneficiaries and
encompasses 1.2 billion individual medical records.
Sample Selection
Patients aged 2 to 17 years of aged (at the start of the year with paid claim) that
had a paid claim for an atypical antipsychotic were included in the analysis. Patients
were then excluded if they lacked continuous eligibility during the claim year or did
not have an associated medical visit in the time frame around the paid claim of
interest.

Continuous eligibility was applied as exclusion criteria to ensure all

prescriptions claims and medical visits were available for analysis. Pediatric patients
included in this analysis were not required to have continuous eligibility for the entire
study period of six years, but only for year of paid AAP claim. Over the study period
from 2010 to 2015 , 43,120 pediatric patients got an AAP paid claim, representing
490,123 paid claims. The final study cohort included 40,750 pediatric patients
(378,007 paid claims for AAPs) with mental health conditions. Medical claims were
collected for all types of services and the diagnoses were coded with the International
Classification of Diseases, 9th Revision and International Classification of Diseases
10th revision—Clinical Modification (ICD-9-CM, ICD-10-CM). Medical claims
associated within a 60-day window of the atypical antipsychotic (AAP) paid claim
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were used to identify associated ICD-9-CM and ICD-10-CM diagnoses (Appendix A)
associated with the prescription. For both analyses, patients and paid claims were
excluded if they had no medical visit within the reference window (+ 60 days around
fill date) to provide clinical information for analysis. Ten diagnosis fields were queried
for the associated reason for the medical visit. Medical visit data was carried forward
for up to one year if it was missing at a particular medical visit. A one-year follow-up
was used to ascertain all relevant clinical information for patients that were likely to
be stabilized on AAP medication therapy and no longer presented to a provider for
monthly medication refills. This ascertainment may explain repeated prescription paid
claims for AAP medication therapy without a more recent medical appointment
associated with the paid claim, since stable patients may be provided refills on an AAP
prescription that do not require repeat monitoring by a provider. Pharmacy claims
were recorded for all outpatient pharmacy plan claims and were coded with National
Drug Codes (NDCs), with detailed information that included medication name, fill
data, days’ supply, quantity and drug strength. All pediatric patients were included in
this analysis regardless of presence of associated mental health diagnosis at the
associated medical visit.
Statistical Analysis
Overall AAP use prevalence was presented as a proportion of the pediatric
population with mental health diagnoses prescribed AAPs in the cohort in the given
year (no. of users per 1,000 children).19 The total number of paid claims, unique
patients and prevalence (represented as a percentage) is described in Table 1. The
total number of children available in dataset was determined by examining all patients
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with at least one paid claim in each year for patients age 2 to 17 years. The number of
paid claims from 2010 to 2015 for AAP medication in pediatric patients were
examined overall and by AAP medication (Figure 1). Among patients with at least
one AAP paid claim and an associated medical visit available for analysis, we
determined the frequency and percentage of baseline patient and clinical
characteristics (Table 2).
We conducted a longitudinal analysis to evaluate the annual rates of AAP use,
both overall and by medication class. Total counts of AAP paid claims per year was
determined per patient. The unit of analysis for this section of the study was the
medical visit for each patient associated with the AAP paid claim, which was then
aggregated to a yearly count per patient. We examined a yearly count to better capture
any market changes that may affect AAP prescribing, such as new drug approvals and
generic formulations. Previous prescribing trends indicated that these market changes
usually influence prescribing patterns over six to twelve months after the change is in
effect.3,4,11,12 The outcome of interest was the count of AAP claims per patients in
each year. As mentioned above, 40,750 patients were included in the study cohort,
representing 378,007 paid claims. The yearly claim count variable was determined by
summing the individual paid claims for AAP medications for a given patient for each
year during the study period. Mental health diagnosis associated with each paid claim
was retained as the primary diagnosis for analysis unless a more recent paid claim was
available with this information. Similarly, the provider details and specialty
information were retained for each patient until a newer paid claim occurred with upto-date information available.
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Because there are multiple visits per patient, a generalized estimating equation
(GEE) model was used to estimate the prevalence of children prescribed AAPs over
time accounting for correlation within patient.20 A GEE model with Poisson variance
and a log-link was used to evaluate the association of covariates with annual claim
count of AAP paid claims per patient over the study period.20 No interaction terms
were included in the final model due to lack of statistical significance of these terms.
Collinearity between independent variables was tested using Variance Inflation
Factors (VIF) test and no significant collinearity was found; thus, no adjustments for
collinearity were made in the final model. Covariates that had a P value < 0.20 in the
unadjusted model were included in the final adjusted model. No independent
variables demonstrated a significant interaction with time over the study period, so no
interactions with time were included in the final model.
We assessed the prevalence of possible off-label diagnostic use of AAPs for
the study period of 2010 to 2015 as a percentage of total AAP prescriptions during that
period. The unit of analysis for off-label use by diagnosis was each patient that
received a paid claim for an AAP medication. Patients contributed multiple claims to
the analysis over the study period and correlation within patient was addressed. To
determine off-label diagnostic use, paid claims were only included if an associated
medical visit of interest was found within the window mentioned above (+ 60 days).
For paid claims that did not have enough time available in study period for complete
analysis, the observation was excluded. For the off-label diagnostic use analysis,
74,841 paid claims (N=37,274patients) were included in the final cohort. A
descriptive analysis evaluated off-label by diagnosis use and results were presented as
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an overall percentage of off-label diagnostic use for each AAP medication. Any
presence of diagnosis associated with AAP use that is off-label by diagnosis during the
study period was considered off-label use, regardless if other diagnoses for a patient
are indicated. Any use of clozapine (Clozaril), iloperidone (Fanapt) and ziprasidone
(Geodon) was considered off-label diagnostic use in this patient population. As of
December 2017, none of these agents have earned a pediatric indication for use from
the FDA. Any off-label diagnostic prescribing was assessed for each paid claim and
patient and provider characteristics associated with that claim were evaluated as
predictors for off-label prescribing. Off-label use can also include use of agents for
unapproved age groups or at doses not approved by FDA indication. For this analysis,
possible off-label use was determined by diagnosis associated with AAP prescription.
Because multiple paid claims per patient were present, a generalized estimating
equation (GEE) model was used to estimate the prevalence of off-label prescribing by
diagnosis of children prescribed AAPs over time, accounting for correlation within
patient.20 A GEE model with binomial variance and a log link was used to evaluate
the association of age, gender, region, provider category and associated mental health
diagnosis as covariates for predicting the off-label diagnostic use of atypical
antipsychotics in the study population.20 This model used a robust estimator of
variance to account for correlation between visits within a patient. No interaction
terms were included in the final model due to lack of statistical significance of these
terms. Collinearity between independent variables was tested using Variance Inflation
Factors (VIF) test and no significant collinearity was found; thus, no adjustments for
collinearity were made in the final model. Mental health diagnosis categories were
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combined as follows due to low sample size in the original seven categories
(Appendix A): Anxiety and Mood disorders; Developmental and DisruptiveAggressive Behavior Disorders; Psychotic, Other Disorders or No Mental Health
Diagnosis present. All covariates with P value < 0.20 were included in the adjusted
model. The final multivariable model was examined for fit using the HosmerLemeshow Goodness of Fit test, which indicated no evidence of a lack of fit (P value
= 0.48). All statistical tests were two-sided and performed at a 0.05 significance level
and analyses were performed using SAS Enterprise Guide Version 7.1 (Cary, North
Carolina, USA).
2.4 Results
Trends in Atypical Antipsychotic Prescribing
From 2010 to 2015, there were 424,722 unique patients (ages 2 to 64 years)
that received at least one atypical antipsychotic medications, with 4,647,014 paid
claims for AAP medications over the entire study period. There were 490,123 paid
claims for AAPs identified representing 78,481 individual pediatric patients (age 2 to
17 years) receiving at least one AAP paid claim over the study period. This represents
an average number of 11.3 paid claims for AAP medications per pediatric patients
over the six-year period.
In the final sample, 378,007 paid claims were evaluated, representing 40,750
individual patients. The use of atypical antipsychotics in this population increased
over the years from 0.19% (2010) to 0.28% (2015). This percentage is out of all
eligible children present in the dataset during the study period. Table 1 and Figure 1
below outline the yearly AAP medication claim count over the study period.
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A full description of baseline characteristics for the study population is
presented in Table 2. The mean age of pediatric patients receiving AAP therapy was
12.7 years (SD=3.7) at time of paid claim. Most patients (55%) were aged 13-17
years or adolescents. Specialty providers were the primary prescribers (40%) of AAP
medication prescriptions. Primary care providers were the second most frequent
prescribers (20%) of AAP prescriptions. At the medical visit associated with the AAP
paid claims, 35% of patients did not have a mental health diagnosis present in the
medical file. With a mental health disorder associated with the AAP paid claim,
Mood disorders were the most common mental health diagnosis (28%), with
Disruptive or Aggressive Behavior disorders the second most common (14%).
Based on the GEE model among the aggregated annual data, the rate ratios of
claim count are presented in Table 3. The final adjusted model demonstrated that
time, gender, age group, region and mental health diagnosis all demonstrated a
significant effect on the rate of paid claims for AAP medications over time in years.
Calendar time was found to have a significant association with the rate of pediatric
patients receiving a paid claim for AAP medications over the study period. With 2010
(baseline) set as the reference point, pediatric patients had a 60% increase rate of claim
count in 2011 (RR=1.6; 95% CI=1.5, 1.7). As the study period progresses, the rate of
AAP paid claims per pediatric patient slightly increased with each calendar year 63%
in 2012, 79% in 2013, 73% in 2014. In 2015, pediatric patients had a 270% increase
in the rate of claim count compared to 2010 (RR=2.7; 95% CI=2.6, 2.9).
Female patients had 10% lower rates of paid AAP claims over the study period
(RR=0.90; 95%CI=0.89, 0.92). Children 2-5 years of age had a 20% increased rate
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(RR=1.2; 95%CI=1.1, 1.2) of paid AAP claims over the study period and children 612 years of age also had a 20% increased rate (RR=1.2; 95% CI=1.1, 1.2) compared to
children 13-17 years old.
Geographic location of the pediatric patient has a small influence on the rate of
paid claims over the study period. Patients living in the Northeast US were found to
have a 4% increase in the rate of AAP paid claims (RR=1.04; 95% CI=1.0, 1.1) and
patients located in the Midwest had a 3% increase rate (RR=1.03; 95% CI=1.0, 1.1)
when compared to patients living in the western US. Overall, region of the US that
patients were located did not have a significant effect on the rate of atypical
antipsychotic prescribing over the study period (P value =0.13).
Mental health diagnosis associated with paid claims had a significant effect on
the rate of AAP paid claims over the study period (P value <0.001). All comparisons
were made to patients that had no mental health diagnosis associated an AAP paid
claims. Patients with an Anxiety Disorder had 14% lower rate of AAP paid claims
over the study period (RR=0.86; 95% CI=0.83, 0.89). Patients with Mood disorders
were found to have a 9% lower rate of AAP paid claims and Disruptive or Aggressive
Behavior (DAB) Disorders were found to have 6% lower rate of AAP paid claims
compared to patients with no present mental health diagnosis (RR=0.91; 95%
CI=0.89, 0.93 and RR=0.94; 95% CI=0.91, 0.97, respectively). Patients with
“Other” mental health diagnoses (Tourette’s Syndrome, Eating Disorders) had a 21%
lower rate of paid claims for AAP medications during the study period (RR=0.79;
95% CI=0.75, 0.82) compared to patients with no present mental health diagnosis.
Patients with developmental disorders and psychotic disorders did not have a
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significantly different rate of paid claims for AAP medications over the study period,
when compared to patients with no mental health diagnosis. Overall, the category of
prescribing provider responsible for the AAP paid claim did not have a significant
effect on the rate of AAP paid claims during the study period.
Off-Label Diagnostic Prescribing of Atypical Antipsychotic Medications
Off-label diagnostic prescribing of atypical antipsychotics was common in
pediatric patients in our study. During the study period, 62% (95% CI=62%, 63%) of
paid claims for atypical antipsychotics in pediatric patients were classified as off-label
diagnostic use. Much of the off-label diagnostic use was due to the lack of mental
health diagnosis present in the medical visit (35%) associated with AAP paid claim.
No diagnostic code for a mental health condition at the medical visit associated with
the paid claim was classified as off-label diagnostic use.
All covariates demonstrated significances as predictor in the univariate
analysis (Table 4). In the final multivariable model, age group (P value=0.05),
gender (P value =0.002), mental health diagnosis (P value<0.001), provider category
(P value=0.08), and US region (P value<0.001) were significant variables in the
likelihood of off-label diagnostic prescribing of AAPs. The adjusted odds ratios are
presented in Table 4. In the adjusted model, children 2-5 years old were 15% more
likely (aOR)=1.15; 95% CI=1.0, 1.3) than children 13-17 years old to be prescribed
atypical antipsychotics for off-label diagnostic indications. Children aged 6-12 years
old were 2% less likely to have off-label diagnostic (aOR=0.98; 95% CI=0.93, 1.0)
use compared to adolescents (ages 13-17 years). Female pediatric patients were 10%
times more likely (aOR=1.1; 95% CI=1.0, 1.2) to be prescribed an AAP in an off-label
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diagnostic manner compared to male children. In the adjusted model, children located
in the Midwest were 13% less likely (aOR=0.87; 95% CI=0.8, 0.97) to have an offlabel diagnostic AAP paid claim, compared to children located in the Northeast.
Similarly, children located in the South US were 16% less likely (aOR=0.84; 95%
CI=0.76, 0.92) to have off-label diagnostic AAP use, compared to children located in
the Northeast. The type of provider that a child received their AAP prescription from
was not a significant predictor of off-label use by diagnosis in the adjusted model,
when compared to prescriptions written by a specialty provider. After adjusting for
other covariates, patients with a documented Mood or Anxiety Disorder were 95% less
likely to receive an AAP medication for an off-label diagnosis (aOR=0.05; 95%
CI=0.048, 0.053) compared to patient with psychotic, other or no mental health
diagnosis present. Also, patients with a documented DAB or developmental disorder
were 97% less likely to receive an AAP medication for an off-label diagnosis
(aOR=0.03; 95% CI=0.03, 0.04) compared to patients with psychotic, other or no
mental health diagnosis present after adjusting for other covariates.
2.5 Discussion
The proportion of children receiving AAP medication therapy in a large private
payer was small (<1%) but still meaningful. Previous studies that included all
children available for AAP prescribing, not only ones with documented mental health
disorders, found similar rates of AAP medication therapy (<1% for children ages 2 to
17).11 This low percentage is still meaningful, because it represents thousands
(N=51,699) of children over the six year study period that are exposed to medications
that have documented metabolic and cardiac long-term effects in adult patients.21,22
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This study included all pediatric patients available in the study dataset during the study
period for the denominator, because all of these patients were at risk for receiving
AAP therapy for any reason, off-label or on-label.
The exposure of these medications during childhood and the long-term effects
on growth and metabolic measures are not clearly understood. Over the last six years,
trends in atypical antipsychotic prescribing demonstrated an overall increase in use
among the privately-insured pediatric population. The primary increase in AAP use
occurred from 2010 to 2011. In 2010, 6,923 (0.19%) children received a paid claim
for an AAP medication. Then in 2011, 8970 (0.25%) children received a paid claim
for an AAP medication. For the remainder of the study years, the prevalence was
stable as illustrated in Table 1. There was a slight increase in prevalence at the end of
the study period, (2015), where 8,745 (0.28%) pediatric patients received AAP
medication therapy. During the study period in our sample, AAP medication
utilization peaked in 2011. This could be due to the increased availability of AAP
medications on the US pharmaceutical market (Figure 1). Overall, by the end of the
study period in 2015, pediatric patients had a 270% increase in AAP paid claim rate
(RR=2.7; 95% CI=2.6, 2.9) compared to the start of the study period in 2010.
Several patient characteristics demonstrated an association with the rate of
AAP paid claims per year over the study period. Gender had a significant association
with the annual rate of paid claims over the study period, with female patients
experiencing lower rates (RR=0.90; 95% CI=0.89, 0.92) of paid claims. Children ages
2-5 years (RR=1.2; 95% CI=1.1, 1.2) and 6-12 years (RR=1.2; 95% CI=1.1, 1.2) had
an increase in the annual rate of paid claims over the study period, compared to older
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children (ages 13-17). This may indicate that over the last six years provider began
utilizing AAP medications in a young patient population as familiarity with the
medication class grows. Geographic location of patient showed an association with
the rate of AAP paid claims over the study period. These minor differences could be
due to local treatment practices and clinical preferences.
Mental health diagnosis associated with the paid claim for an AAP
demonstrated a significant association with the rate of AAP paid claims over the study
period. Patients with Developmental Disorders and Psychotic Disorders did not have
a significantly different rate of paid claims for AAP medications over the study period,
when compared to patients with no mental health diagnosis. This is finding is
surprising, because previous trend studies have shown that use of atypical
antipsychotics for Developmental Disorders was increasing overall and represented
the highest rate of utilization compared to other mental health disorders. Our study
population had a much lower percentage of patients with Developmental Disorder
(4%) compared to previous literature (53%).4 All clinical categories of mental health
diagnoses were compared to the absence of mental health diagnosis in the medical
visit around the paid claim. In our study, 35% of paid claims did not have an
associated mental health diagnosis. Providers may withhold the documentation of
mental health diagnosis due to potential stigma that could follow a pediatric patient
through to adulthood.11,23 Some antipsychotics could be utilized for treatment for other
conditions (insomnia, agitation) that do not meet clinical criteria as a mental health
disorder.11,24 Finally, provider specialty or category did not demonstrate an
association with the rate of paid AAP claims over the study period. Our study found
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that whether a patient is seen by a primary care provider or a mental health specialist,
the rate of AAP prescribing is comparable.
Off-label prescribing can describe the use of medication therapy for indications
that are not officially approved by the Food and Drug Administration. Off-label use
also includes using medications for unapproved age groups and at unapproved dosing
levels for certain populations. This study defined off-label diagnostic use as
prescribing of an AAP medication with no documented mental health disorder or an
unapproved mental health disorder. Future studies should explore dosing levels of
AAP paid claims and differentiated age groups to examine all types of off-label
prescribing. Off-label use of atypical antipsychotic agents in pediatric patients is
heavily debated.17,25 Many AAP medications have limited or no official FDA
indication in children due to lack of research evidence in pediatric patients. Our study
found that off-label diagnostic prescribing of AAP medications occurred in 62% (95%
CI=62%, 63%) of all paid claims. This means that providers and patients were using
AAP medications for other mental health diagnoses that have not been formally
studied and approved by the FDA. Our study found that off-label prescribing of
atypical antipsychotics is common in the pediatric population.
2.6 Limitations
Our study assumed that a paid claim for an AAP represents therapy adhered to
by the patient. This assumes that the patient is exposed to a given medication because
the paid claim was processed and therefore the patient adhered to the regimen. This
could overestimate the actual exposure to AAP medication therapy because patients
may have been prescribed the AAP medication, but never actually consume the
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prescription. For the purposes of this study, only prescribing trends were evaluated,
and outcomes based on patient exposure were not examined.

Future research that

explores outcomes related to exposure of AAP could perform patient surveys or pill
count methods to confirm the exposure to AAP medication therapy.
A sizable percentage (35%) of paid claims for AAP medications was not
associated with a mental health diagnosis of interest. All patients included in the
original cohort had a mental health diagnosis of interest to warrant inclusion in the
cohort. With so many patients missing a mental health diagnosis at associated medical
visit, the rate of other categories of mental health disorder might be underrepresented.
Many patients could have a diagnosis in one of the categories, but it is not documented
and recorded in the “missing” category. This can underestimate the true rate of the
mental health diagnostic categories that are used for off-label analysis. The lack of a
mental health diagnosis associated with an AAP paid claim constituted off-label
prescribing for the purposes of this study. This could be overestimating the rate of
off-label diagnostic use of AAP medications in this study because provider could have
simply failed to properly document the reason for AAP use and this undocumented
reason could align with an approved FDA indication. Providers could justify this to
protect a patient from the bias or stigma of mental health disease by not documenting a
mental health diagnosis at medical visits.
2.7 Conclusions
Overall, the proportion of the pediatric population in a large privately-insured
cohort receiving AAP medication therapy was small 0.28% (2015). From 2010 to
2015, atypical antipsychotic prescribing in privately-insured pediatric patients
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increased from 0.19% in 2010 to 0.28% in 2015. At the end of the study period,
pediatric patients had a 270% increase in the rate of atypical antipsychotic prescribing
per year compared to 2010. Off-label prescribing represented 62% of atypical
antipsychotic medication use and our study found it to be frequent practice in the
pediatric population. Several AAP agents (clozapine, ziprasidone and iloperidone)
with no pediatric indication at all were still found to be used in the study population
(6.7%). Patients ages 2 to 5 years old were at an increased risk for using atypical
antipsychotic medications for off-label diagnoses. Female patients were at increased
risk for using atypical antipsychotic medications for off-label diagnoses. With these
new insights, providers should consider more stringent use of atypical antipsychotic
agents based on diagnosis until further safety studies are available specific to pediatric
patients.

62

2.8 References
1.

Halloran DR, Swindle J, Takemoto SK, Schnitzler MA. Multiple Psychiatric
Diagnoses Common in Privately Insured Children on Atypical Antipsychotics.
Clin Pediatr (Phila). 2010;49(5):1-11.

2.

Kumar A, Datta S, Wright S, Furtado V, Russell P. Atypical Antipsychotics for
Psychosis in Adolescents (Review). Cochrane Database of Systematic Reviews;
2013.

3.

Crystal S, Mackie T, Fenton MC, et al. Rapid Growth of Antipsychotic
Prescriptions for Children Who Are Publicly Insured Has Ceased, But Concerns
Remain. Health Aff (Millwood). 2016;35(6):974-982.

4.

Cooper W, Arbogast P, Ding H. Trends in Prescribing of antipsychotic
Medications for US children. Ambul Pediatr. 2006;6:79-83.

5.

Patel N, Crismon M, Shafer A. Diagnoses and Antipsychotic Treatment among
Youth in a Public Mental Health System. Ann Pharmacother. 2006;40:205-211.

6.

Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T. Diagnoses Associated
with Use of Atypical Antipsychotics in a Commercial Health Plan: A Claims
Database Analysis. Clin Ther. 2013;35(12):1867-1875.

7.

Patel N, Crismon M, Hoagwood K. Trends in the use of typical and atypical
antipsychotics in children and adolescents. J Am Academy Child Adolesc
Psychiatry. 2005;44:548-559.

8.

Correll C. Antipsychotic use in children and adolescents: minimizing adverse
effects to maximize outcomes. J Am Academy Child Adolesc Psychiatry.
2008;47:9-20.

9.

Curtis L, Masselink L, Ostbye T. Prevalence of Atypical Antipsychotic Drug Use
Among Commercially Insured Youth in the United States. Arch Pediatr Adolesc
Med. 2005;159:362-366.

10. Drugs@FDA: FDA Approved Drug Products. March 2017.
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed March 20,
2016.
11. Olfson M, King M, Schoenbaum M. Treatment of Young People with
Antipsychotic Medications in the United States. JAMA Psychiatry.
2015;72(9):867-874.
12. Zito J, Safer D, DosReis S, et al. Psychotropic practice patterns for youth: a 10year perspective. Arch Pediatr Adolesc Med. 2003;15:717-725.

63

13. Leslie D, Rosenheck R, Horwitz S. Patterns of mental health utilization and costs
among children in a privately insured population. Health Serv Res J.
14. Cooper W, Hickson G, Fuchs C, Arbogast P, Ray P. New Users of antipsychotic
medications among children enrolled in TennCare. Arch Pediatr Adolesc Med.
2004;15(8):753-759.
15. Staller J, Wade M, Baker M. Current prescribing patterns in outpatient child and
adolescent psychiatric practice in central New York. J Child Adolscent
Psychopharmacol. 2005:1557-1561.
16. Kogut SJ, Yam F, Dufresne R. Prescribing of Antipsychotic Medication in a
Medicaid Population: Use of Polytherapy and Off-Label Dosages. J Manag Care
Pharm. 2005;11(1):17-24.
17. Alexander G, Gallagher S, Mascola A, Moloney R, Stafford R. Increasing offlabel use of antipsychotic medications in the United States, 1995–2008.
Pharmacoepidemiol Drug Saf. 2011;20(2):177-184.
18. OPTUM. OPTUM (R) Clinformatics DataMart: DataSheet. 2016.
https://www.optum.com/content/dam/optum/resources/productSheets/Clinformat
ics_for_Data_Mart.pdf. Accessed March 26, 2017.
19. Foster PD, MMath XC, Vigod S, et al. Trends in the Use and Cost of
antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional
study. Can Med Assoc J. 2016;4(2):E292-97.
20. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. 2nd
Edition. Boston, MA: Wiley; 2011.
21. Caccia S. Safety and Pharmacokinetics of Atypical Antipsychotics in Children
and Adolescents. Pediatr Drugs. 2013;15:21-233.
22. Stroup T, McEvoy J, Ring K, et al. A randomized trial examining the
effectiveness of switching from olanzapine, quetiapine, or risperidone to
aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic
problems (CAMP). Am J Psychiatry. 2011;168(9):947-956.
23. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National Trends in the Outpatient
Treatment of Children and Adolescents with Antipsychotic Drugs. Arch Gen
Psychiatr. 2006;63:679-685.
24. Anderson S, Vande Griend J. Quetiapine for insomnia: a review of the literature.
Am J Health-Syst Pharm. 2014;71(5):394-402.
25. Zito J, Derivan A, Kratochvil C, Safer D, Fegert J, Greenhill L. Off-label
psychopharmacologic prescribing for children: History supports close clinical
monitoring. Child Adolesc Psychiatry Ment Health. 2008;2(24).
64

Table 1. Atypical Antipsychotic Paid Claims for US Privately-Insured Children (2 to 17 years)
from 2010 to 2015 (N=51,669 pediatric patients with 378,007 paid claims)
Group
Number of Eligible
Pediatric patients in
claims database
Number of AAP paid
claims among
children
Number of pediatric
patients with at least
one paid claim for an
AAP medication
Percentage of
Children receiving
paid claim for AAP
medication

2010
3,562,685

2011
3,525,172

2012
3,474,515

2013
3,404,207

2014
3,308,273

2015
3,182,170

50,976

67,586

71,712

70,077

62,416

55,240

6923

8970

9507

9091

8433

8745

0.19%

0.25%

0.27%

0.27%

0.25%

0.28%

Figure 1. Percentage of Total Paid Claims (displayed by medication) for US Privately-Insured
Children (2 to 17 years) for an Atypical Antipsychotic (2010 to 2015).
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Table 2. Baseline Patient and Clinical Characteristics of US Privately-Insured Children (2 to 17
years) Receiving an Atypical Antipsychotic (AAP) Medication from 2010 to 2015 (N=40,750)
Characteristic

Pediatric Patients with an AAP Paid Claim
(N=40,750)

Age, y (mean, SD)
Age Group, n (%)
2-5 Years
6-12 Years
13-17 Years
Male, n (%)
US Region, n (%)
Northeast
Midwest
West
South
Provider type, n (%)
Acute Care Hospital
Mental Health Professional (non-physician)
Outpatient Facility
Primary Care Provider
Specialist
Therapy Provider (Social Worker, Psychologist)
Other Non-Physician Provider
Diagnosis associated with AAP prescription, n (%)
Anxiety Disorders
Mood Disorders
Disruptive or Aggressive Behavior Disorders
Developmental Disorders
Psychotic Disorders
Other MH Disorders
No MH Diagnosis Present

12.7 (3.7)
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2512 (6)
15913 (39)
22325 (55)
23139 (57)
4261 (11)
11802 (29)
7332 (18)
17355 (43)
1910 (5)
4089 (10)
2368 (6)
8029 (20)
16077 (40)
2450 (6)
5827 (14)
4465 (11)
11449 (28)
5509 (14)
1495 (4)
1407 (4)
2265 (6)
14160 (35)

Table 3. Rate Ratios (RRs) with 95% Confidence Intervals (CIs) Derived From an Adjusted GEE
Model of Patient and Clinical Factors Associated with Prescribing of Atypical Antipsychotic
Medication in US Privately-Insured Pediatric Patients (2 to 17 years) from 2010 to 2015.
(N=40,750)
Variable
Rate Ratios (95% CI’s)
p-value
Time (Study Year)
2010
2011
2012
2013
2014
2015
Gender
Male
Female
Age Group
2-5 Years
6-12 Years
13-17 Years
Region
Northeast
Midwest
South
West
Mental Health Diagnosis
Anxiety Disorders
Mood Disorders
Disruptive or Aggressive Behavior
Disorders
Developmental Disorders
Psychotic Disorders
Other Mental Health Disorders
No Mental Health Diagnosis Present
Provider Category
Acute Care Hospital
Mental Health Professional (non-physician)
Outpatient Facility
Primary Care Provider
Specialist
Therapy Provider (Social Worker,
Psychologist)
Other non-physician provider

<0.001
Reference
1.57 (1.5, 1.7)
1.63 (1.5, 1.7)
1.79 (1.7, 1.9)
1.74 (1.7, 1.8)
2.71 (2.6, 2.9)
<0.001
Reference
0.90 (0.89, 0.92)
<0.001
1.2 (1.1, 1.2)
1.2 (1.1, 1.2)
Reference
0.13
1.04 (1.0, 1.1)
1.03 (1.0, 1.1)
1.0 (0.98, 1.0)
Reference
<0.001
0.86 (0.83, 0.89)
0.91 (0.89, 0.93)
0.94 (0.91, 0.97)
1.1 (0.99, 1.0)
1.1 (1.0, 1.2)
0.79 (0.75, 0.82)
Reference
0.35
1.0 (0.97, 1.1)
1.0 (0.98, 1.1)
1.1 (1.0, 1.1)
1.0 (0.98, 1.1)
1.0 (0.99, 1.1)
1.0 (0.95, 1.1)
Reference

*General estimating equations used with a Poisson variance and log-link. Final model adjusted for the following
baseline covariates: Age group, gender, US region and Mental Health Diagnosis.
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Table 4. Odds Ratios (ORs) with 95% Confidence Intervals (CIs) Derived from an Adjusted
GEE Model of Patient and Clinical Factors Associated with Any Off-Label Diagnostic
Prescribing of Atypical Antipsychotic Medication in US Privately-Insured Pediatric Patients (2 to
17 years) from 2010 to 2015. (N=37,274 patients; 78,481 paid claims)
Variable
Odds Ratios (95% CIs)
p-value
Patient Age
Age Group (years)
2-5 years
6-12 years
13-17 years (adolescents)
Gender
Female
Male
Region
Midwest
South
West
Northeast
Mental Health Diagnosis**
Anxiety or Mood Disorders
DAB*** and Developmental
Disorders

1.0 (1.0, 1.1)

Psychotic, Other or NO MH Diagnosis
Present

Reference

Provider Category
Acute Care Hospital
Mental Health Professional (nonphysician)
Outpatient Facility
Primary Care Provider
Specialist
Therapy Provider (Social Worker,
Psychologist)
Other non-physician provider

0.05
0.05

1.15 (1.0, 1.3)
0.98 (0.93, 1.0)
Reference
0.002
1.1 (1.0, 1.2)
Reference
<0.001
0.8 (0.80, 0.97)
0.84 (0.76, 0.92)
0.99 (0.89, 1.1)
Reference
<0.001
0.05 (0.05, 0.06)
0.03 (0.03, 0.04)

0.08
1.1 (0.98, 1.2)
1.0 (0.97, 1.1)
0.98 (0.91, 1.1)
1.0 (0.98, 1.1)
Reference
1.0 (1.0, 1.2)
1.1 (1.0, 1.1)

*General estimating equations used with a Binomial variance and log-link. Final model adjusted for the following
baseline covariates: Age group, gender, US region, Mental Health Diagnosis, and Provider category.
**Mental Health Diagnosis categories combined as described in above table. Patients receiving medication offlabel did not have any diagnosis of Disruptive/Aggressive Behavior Disorders or Psychotic Disorders noted.
Patients receiving medications “on-label” did not have any diagnoses of Anxiety Disorders, Developmental
Disorders, Other Disorders or Missing.
***Disruptive and Aggressive behavior (DAB)

68

MANUSCRIPT 3
Title: Risk of Psychiatric Readmission in Pediatric Patients Treated with Oral
Atypical Antipsychotics
Kellye Donovan, PharmD, MHA1; Ashley Buchanan, DrPH, MS1; Stephen Kogut,
PhD, MBA1; Robert Laforge, Sc.D2
1Program

in Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy Practice, College of
Pharmacy, University of Rhode Island, Kingston, RI
2Director of Behavioral Science Program, Department of Psychology, College of Health Sciences, University of
Rhode Island, Kingston, RI

Corresponding Author: Kellye Donovan, College of Pharmacy, University of Rhode
Island , 7 Greenhouse Rd , Kingston, RI, email: kloethen@my.uri.edu
Funding: Unfunded
Target Journal: Pediatrics: The Journal of the American Academy of Pediatrics
Publication Status: In preparation

69

3.1 Abstract
OBJECTIVE: This analysis aims to determine the risk of readmission for mental
health treatment for pediatric patients treated with oral atypical antipsychotics (AAPs)
upon discharge from initial mental health inpatient admission. Examine patient and
clinical characteristics that are associated with risk of readmission with oral atypical
antipsychotic treatment.
METHODS: Inpatient hospitalization and pharmacy claims from the OPTUMInsight
administrative dataset (Optum Clinformatics ® Data Mart; OptumInsight, Eden
Prairie, MN) from 2010 to 2015 were analyzed. Children ages 2 to 17 years old with
an inpatient admission for a mental health diagnosis of interest and discharged on an
oral AAP were included in the study sample (N =3,028). A Cox proportional hazards
regression model was used to evaluate if exposure to different oral AAPs agents,
including risperidone, aripiprazole, quetiapine, etc., was associated with a delay in the
time until readmission for mental health stabilization. Other patient and clinical
characteristics and their association with delayed time until readmission was analyzed.
RESULTS: For all children with an index admission for mental health treatment, the
mean age of the study cohort was 14.8 years (standard deviation (SD) = 2.3). Of all
3,084 patients, 85% of patients were aged 13-17 years old or in adolescence. The
cohort had slightly more male patients than female patients, (59% vs. 46%, P
value<0.001). In pediatric patients admitted for mental health treatment, 73% of
patients had a Mood Disorder as their primary mental health diagnosis (P value=
0.02). In the study cohort, aripiprazole was the more frequently utilized discharge
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AAP (42%). Overall, the Charlson Comorbidity Index (CCI) score for the entire
cohort was not significantly different between the groups and most patients (92%)
included in this cohort had a CCI score of zero. In the analysis examined by discharge
AAP, patients receiving risperidone were younger (13.6, SD=2.8, P value <0.001)
compared to other discharge AAPs. More male patients received risperidone as a
discharge AAP, (70%, p<0.001) compared to other AAP agents. Children with a
primary mental health diagnosis of Mood Disorders received aripiprazole, quetiapine
or ziprasidone more often for discharge therapy (80%, 76%, 75%, respectively; P
value <0.001) than other AAP agents. In the unadjusted model, quetiapine (hazard
ratio (HR)=0.69, 95% confidence interval (95% CI)=0.47, 1.0) and ziprasidone
(HR=0.52, 95% CI=0.28, 0.97) prescribed for a patient upon discharge form index
admission demonstrated a significant lower risk of readmission, compared to
risperidone.
In the adjusted Cox proportional hazards model, female gender was associated with a
significantly higher risk (adjusted hazard ratio (aHR) =1.5, 95% CI=1.2, 1.8), of
readmission for mental health treatment. Patients with no prior treatment with AAP
medication before index admission were 8.9 times more likely (aHR=8.9, 95%
CI=3.7, 21.8) to be readmitted for mental health treatment. In the adjusted model,
patients receiving quetiapine (aHR=0.55, CI=0.37, 0.81) and ziprasidone (aHR=0.55,
CI=0.29, 1.0) upon discharge had a lower risk of readmission, compared to
risperidone. In the weighted cumulative incidence curves, 13% of patients receiving
risperidone, 12.5% of patients who were taking aripiprazole and 10 % of patient
receiving olanzapine were readmitted within the follow-up period. In comparison, 7%
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of patient receiving quetiapine and 5.5% of patients receiving ziprasidone were
readmitted within the follow-up period.
CONCLUSIONS: Patients receiving quetiapine and ziprasidone had a lower risk of
readmission, compared to risperidone when used at discharge in pediatric patients.
The cumulative incidence of readmission was lower in patients receiving quetiapine
and ziprasidone upon discharge. Pediatric patients of a female gender had a
significantly higher risk of readmission. Patients with no recent prior exposure to
AAP mediation therapy in the 3-month prior to index admission were at a much higher
risk of readmission for mental health treatment. Future studies should examine the
adverse events of these agents in the pediatric population. This additional safety data
can determine if these agents should be considered for increased use in clinical
practice for in pediatric patients to reduce the risk of readmission for mental health
treatment.
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3.2 Introduction
Several randomized, controlled trials have demonstrated that atypical
antipsychotic medications, such as risperidone, olanzapine, aripiprazole and
quetiapine, produce fewer adverse effects and offer better psychotic symptom relief in
a short course than other agents in pediatric patients with mental health disorders.1–6
However, there is limited information available about the comparative effectiveness of
these medications in clinical practice settings, specifically in pediatric patients.7 A
major indication of drug effectiveness in clinical practice is relapse. In regards to
mental health disorders, this relapse is characterized by worsening symptoms or
changes in behavior that become harmful to the patient and/or society.8 Time to
readmission for inpatient mental health treatment is a commonly used measure for
assessing relapse and effectiveness of mental health therapies.8,9 Available follow-up
studies in adults indicate that up to 50% of patients with schizophrenia and other
psychotic disorders are readmitted within one year post discharge.10,11 This high rate
of readmission is particularly concerning because a higher rate of relapse is associated
with worse long-term prognosis in adult mental health patients.11 . Poor adherence to
antipsychotic therapy has been shown to increase risk of relapse and hospitalization
with a related increase in related healthcare resource utilization and costs.12–15 Patients
often try several antipsychotic agents over the course of treatment due to side effects
or varying efficacy in the individual patient. No studies are yet available comparing
the rates of readmission with atypical antipsychotics in pediatric patients
According to 2008 research using data from the Healthcare Cost and
Utilization Project (HCUP), there were 356,000 hospital admissions for psychotic
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disorders in the US, representing 19% of all mental health hospitalizations.16 These
patients had an average length of stay of 11.1 days and average cost per admission was
$7,500.16,17 Patients who experienced a recent relapse (within previous 6 months)
were found to have four times higher costs compared to patients without a recent
mental health relapse.17 This study focused primarily on adult patients and only
included patients diagnosed with schizophrenia12,13,16,17 A 2014 report analyzing
admissions for mental health treatment in pediatric patients estimated the cost of
hospital visits (inpatient and emergency department) to be $11.6 million from 2006 to
2011, based on HCUP data.18

In 2014, 10% of all hospitalizations in children over

the age of 3 years were for a primary mental health diagnosis.19 Previous research
followed adult schizophrenic patients for two years and found statistically significant
differences between atypical antipsychotic agents in regards to risk of increased
readmission rates.9,20 To the best of our knowledge, no study has yet examined a
direct comparison of oral atypical antipsychotic agents in privately-insured pediatric
patients with mental health conditions to delay hospital readmission for mental health
treatment.
This study focused on pediatric patients who utilized oral atypical
antipsychotic therapy after an initial admission for mental health treatment.
Readmission for mental health treatment was evaluated to determine the efficacy of
using specific atypical antipsychotics in pediatric mental health patients. Many
randomized controlled trials and post-marketing trials demonstrated the efficacy of
individual oral agents in the reduction in readmission in adults patients, compared to
placebo or first generation antipsychotics.21–23 Furthermore, clinical providers often
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extrapolate the demonstrated benefit of these agents in adults to pediatric patients with
limited direct evaluation among children.24 This study evaluated the effectiveness of
specific oral AAP agents in delaying readmission in pediatric patients.
3.3 Methods
Study Design
The study was a retrospective cohort study utilizing the administrative dataset
(Optum Clinformatics ® Data Mart; OptumInsight, Eden Prairie, MN) from January 1,
2010 to December 31, 2015. This data set contains medical, including inpatient and
outpatient, and relevant information about hospital admissions. This data included
commercial health insurance claims (inpatient and outpatient medical records,
laboratory data, facility information, and outpatient pharmacy) and enrollment data
from large, private insurer across the United States.25 This dataset provides healthcare
information on 36 million beneficiaries and encompasses 1.2 billion individual
medical records. Pediatric patients represent about 10% of this dataset or 3.5 million
children. The inpatient admission file provided clinical information on date of
admission, diagnosis codes for admission, length of stay (LOS) and discharge date.
The inpatient file contains up to five diagnoses associated with an admission or
encounter available for evaluation. Pharmacy claims data included medication
information such as days’ supply, quantity, prescribing physician and cost data. This
dataset represents approximately 36 million covered patients across the United States.
The index date was the date of the first hospital admission for a mental health
diagnosis during the study period. A look-back period of 90 days from index
admission date was examined to ensure no prior admission for mental health treatment
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was present.

Patients were followed for up to one year from the discharge date of the

index hospitalization. According to studies evaluating inpatient mental health
treatment in adults, the highest risk of readmission is in the first-year post-discharge,
so this same follow-up period was chosen.
Inclusion Criteria
The study included all patients with an inpatient admission for a mental health
diagnosis aged 2-17 years. Admission for a mental health diagnosis was determined
by utilizing International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) and International Classification of Diseases, Tenth
Revision, Clinical Modification (ICD-10-CM) diagnostic codes listed in Appendix A.
Eligible patients required at least 90 days or continuous health plan enrollment before
index admission and 365 days after the index admission.9, 24 Patients were included
only if they received an atypical antipsychotic medication (AAP) upon discharge from
index admission. Patients were identified as having an AAP medication paid claim
using National Drug Codes (NDCs) as provided in Appendix B, for an available AAP
medication on the US market. All available dosage forms and atypical antipsychotic
medications were included in the analysis. Patients were determined to have received
an AAP medication upon discharge if a paid claim was present for an AAP within 14
days post discharge date.
Exclusion Criteria
Patients will be excluded from the study if they were older than 17 years at
index hospitalization and no paid claim within 14 days for atypical antipsychotic
medication therapy.9, 24 The 14-day post discharge date window was used to identify a
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paid claim as representing a discharge prescription from the index admission. This
window was defined based on clinical practice parameters from the American
Academy of Child and Adolescent Psychiatry that recommend follow-up
appointments post hospitalization occur within 7-14 days to provide continuity of care
across levels of mental health treatment.26 Patients who were hospitalized for mental
health treatment during the study period in the recent months preceding the index
admission were excluded. A look back period of 90-days was examined for any recent
admissions for mental health treatment. Patients were included in study cohort if their
index admission was for a mental health diagnosis. A 90-day look back period from
index admission was performed to examine prior exposure to AAP therapy and
patients were classified as having no prior exposure, exposure to same AAP as
discharge agent or exposure to different AAP as discharge medication. Figure 1
describes the study cohort with relevant exclusion or inclusion criteria.
Exposures and Outcomes
The exposure of interest was the use of atypical antipsychotic therapy at time
of hospital discharge.20 Exposure to specific AAP agents was evaluated and each
agent was compared to risperidone. Risperidone was chosen as the reference agent
because it was the first atypical antipsychotic to be awarded an Food and Drug
Administration (FDA) indication for use in pediatric patients. The primary outcome
evaluated was time from index hospital discharge to readmission for any mental-health
related diagnosis (Appendix A).
Covariates considered sufficient to adjust for confounding included the
following at baseline: age, gender, admission diagnosis, length of hospital stay,
Charlson Comorbidity Index (CCI) and AAP exposure (same AAP as discharge,
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different AAP as discharge or no AAP therapy) prior to index hospitalization.
Admission diagnosis was categorized in to groups listed in Appendix A and compared
to diagnosis codes in the “other” category. The other category was used as the
reference group because it contains mental health diagnoses that AAP agents do not
have a FDA approved indication and should have the lowest exposure risk to AAPs
since no official FDA indication is present. The CCI score was used to evaluate the
severity of illness among patients at their index hosptialization.27 The CCI score
measures the severity of the presence of certain disease states, such as malignancies,
HIV, and diabetes, in the patient’s inpatient medical file at index admission and
represents the overall health status of the patient. Appendix C provides a full listing
of the disease states included in the CCI score and point values associated with each
diagnosis. Length of stay (LOS) of index admission was examined as a covariate and
represented in number of days as a continuous variable. Patients were followed to
ascertain hospital readmission with a related MH diagnosis and were censored at the
date of death (as recorded in a hospital claim), one-year post discharge of the index
admission or end of the study period (31 December 2015), whichever occurred first.
Statistical Analysis
We reported descriptive statistics to characterize each outcome group of
interest (readmission for mental health treatment or no readmission). Baseline
characteristics were also examined by discharge AAP (exposure group) and presented
in Table 2. Group comparisons on baseline sample characteristics were performed
using chi-square tests or Fisher-exact tests for categorical variables and Analysis of
Variance (ANOVA) for continuous variables. Baseline characteristics of patients at
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index discharge were examined and included covariates age, gender and United States
region. We used a Cox proportional hazards regression model to assess hazard (i.e.,
risk) of psychiatric readmission post-discharge within one year of index admission.
Baseline covariates for adjustment in the models included age group, gender, index
admission diagnosis, CCI score, region, pre-index AAP exposure and discharge AAP
agent.28,29 The Schoenfeld residuals were examined to determine if the proportional
hazard assumption was violated.29 All covariates except for age showed no evidence
of a violation of proportional hazards through this statistical test [(LOS, P
value=0.36), (Gender, P Value=0.84), (Region, P Value=0.26), (CCI Score, P
Value=0.98), (MH Diagnosis, P Value=0.12), (Prior AAP exposure, P Value=0.37)
and (Discharge AAP, P Value=0.14)]. The proportional hazard assumption for the
covariate age group was not satisfied (P value = 0.02); therefore, the model was
stratified by age group to allow for separate baseline hazards for each age group.30 All
pairwise interactions between covariates were not statistically significant in a single
contrast (P value=0.56). These values indicated that none of the interactions of
covariates were significant, so interaction terms were not included in the final model.
Collinearity between independent variables was tested using Variance Inflation
Factors (VIF) test and no significant collinearity was found; thus, no adjustments for
collinearity were made in the final model. Covariates associated with the outcome
with P value less than 0.20 in the univariate analysis were included in the final
adjusted model.28 Gender (P value<0.001), prior AAP mediation exposure (P value
<0.001), mental health diagnosis (P value=0.11) and discharge AAP medication (P
value=0.14) demonstrated a significant effect on risk of readmission during the study
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period and all of these covariates were included in the adjusted model. CCI score was
non-significant and was not included in the adjusted analysis. The length of stay
(LOS) was not found to have a significant effect on risk of increased readmission and
LOS was not included in the adjusted model. We used Efron’s method to handle tied
event times.29,31 Cumulative incidence curves were generated using inverse
probability weights to adjust for the baseline covariates. All statistical tests were twosided and performed at the 0.05 significance level. Analyses were performed using
SAS Enterprise Guide Version 7.1 (Cary, North Carolina, USA).
3.4 Results
During the study period 2010 to 2015, 3,215 pediatric patients were admitted
with a mental health diagnosis documented as the reason for admission. After applying
inclusion criteria of receiving an AAP medication upon discharge (within 14-day
window), 3,084 patients had a qualifying index admission for mental health treatment
during the study period. Of those subjects, 313 (10%) children had a readmission
within one year of the index admission discharge date for a mental health diagnosis or
readmission for mental health treatment. The study sample is presented in Figure 1.
Study Cohort disposition and characteristics
For the entire cohort, the mean age of the study cohort was 14.8 years
(standard deviation (SD) = 2.3). Of all patients evaluated, 85% of patients were ages
13-17 years old or adolescents. The cohort had slightly more male patients than
female patients, (53% vs. 47%). In pediatric patients admitted for mental health
treatment, 73% of patients had a Mood Disorder as their primary mental health
diagnosis (72.5%). In the study cohort, aripiprazole was the more frequently utilized
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discharge AAP (41.8%). Overall the CCI score for the entire cohort was not
significantly different between the groups (patients readmitted vs. patients not
readmitted) and most patients (92%) included in this cohort had a CCI score of zero
(Table 1). This was expected since the components of the CCI score are primarily
chronic illnesses and these conditions are usually present in higher frequencies as a
population ages.
Baseline characteristics of readmission versus no readmission patients are
displayed in Table 1. Children readmitted for mental health treatment during the
follow up period were slightly higher in age (15.2 years. vs. 14.7 yrs., P value=0.006).
The group that was readmitted for mental health treatment has a significantly larger
proportion of female patients (59% vs 46%, P value<0.001). The percentage of
children with no prior AAP exposure in the three months preceding index admission
was higher in readmitted group compared to the children not readmitted within the
follow-up period (91.7% vs. 59.7%, P value<0.001). The admission mental health
diagnosis differed significantly between the children readmitted for treatment, and
those that were not (P value=0.007). Children readmitted for mental health treatment
had a higher proportion of documented diagnoses for Mood Disorders (77% vs. 72%)
than children not readmitted. Children readmitted for mental health treatment had a
lower proportion of documented diagnoses for Disruptive or Aggressive Behavior
Disorders (5% vs. 9%). The mean length of index hospital admission did not
significantly vary between the two groups (8.2 days vs. 8.0 days, P value =0.85). The
region of residence did not vary significantly between the two groups (P value=0.60).
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The CCI score was zero in 92% of patients in both groups and was not significantly
different (P Value =0.86).
Baseline characteristics of children in the cohort analyzed by exposure
(discharge atypical antipsychotic agent) are presented in Table 2. Patients receiving
risperidone were younger (13.6, SD=2.8, P value<0.001) compared to other discharge
AAPs. More male patients received risperidone as a discharge AAP, (70%, P
value<0.001) compared to other AAP agents (47%). Children receiving risperidone
upon discharge had documented disruptive or aggressive behavior disorders as
primary diagnosis more often than children receiving other AAP agents upon
discharge (13% vs. 7%, respectively; P value<0.001). Children with a primary mental
health diagnosis of Mood Disorders received quetiapine, aripiprazole or ziprasidone
more often for discharge therapy (80%, 76% and 75%, respectively; P value <0.001)
compared to other AAP agents. CCI score did not vary significantly between
discharge AAP exposure groups at baseline.
Table 3 summarizes the results of the unadjusted and adjusted models. In the
unadjusted model, several baseline patient characteristics displayed a significant
association with the hazard of readmission for mental health treatment. Female
patients had a 60% increased risk of readmission (hazard ratio, (HR) =1.6; 95%
confidence interval, (CI) =1.2, 2.5) compared to male patients. Patients with a
primary diagnosis of disruptive or aggressive behaviors disorders (DAB) had a 55%
decreased risk of readmission (HR=0.45; 95% CI=0.23, 0.89) compared to children
with a diagnosis of other mental health disorders. Similarly, patients with a primary
diagnosis of Developmental Disorders had a 65% decreased risk of readmission
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(HR=0.35; 95% CI=0.12, 0.98) compared to children diagnosed with other mental
health disorders. Children with no prior AAP exposure in the three months prior to
index admission were 10 times more likely to be readmitted for mental health
treatment (HR=10.2; 95% CI=4.2, 24.7). Patients receiving quetiapine had a 31%
decreased risk of readmission (HR=0.69; 95% CI=0.47, 1.0) compared to patients
receiving risperidone. In the unadjusted model, patients receiving ziprasidone had a
48% decreased risk of readmission (HR = 0.52; 95% CI = 0.28, 0.97) compared to
patients receiving risperidone. Finally, patients receiving “other” AAP agents
(lurasidone, asenapine, clozapine, iloperidone and paliperidone) had a 71% decrease
risk of readmission for mental health treatment (HR=0.29; 95% CI=0.11, 0.79)
compared to risperidone. CCI score was zero in 92% in patients at baseline and was
not included in Cox proportional hazard model. LOS (P value =0.70) and geographic
region (P value=0.93) were not significantly associated with time to readmission.
In the adjusted Cox proportional hazards analysis, female patients had 50%
increased risk of readmission for mental health treatment (adjusted hazard ratio
(aHR)=1.5; 95% CI =1.2, 1.8). Patients with no prior treatment with AAP medication
before index admission had 8.9 times the risk (aHR=8.9; 95% CI=3.7, 21.8) of
readmission for mental health treatment. In the final adjusted model, choice of atypical
antipsychotic agent for discharge therapy demonstrated a significant effect on the risk
of readmission. Patients receiving quetiapine at discharge had a 45% decreased risk
(aHR=0.55; 95% CI=0.37, 0.81) and patients receiving ziprasidone had a 45%
decreased risk (aHR=0.55; 95% CI=0.29, 1.0) of being readmitted for mental health
treatment, compared to patients receiving risperidone. In the adjusted model, primary
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mental health diagnosis was no longer significantly associated with the hazard of
being readmitted for mental health treatment during the follow-up period (P value =
0.14).
The unadjusted cumulative incidence of readmission is presented in Figure 2
and the inverse probability weighted cumulative incidence curves are presented in
Figure 3, examined by discharge AAP agents. In the unadjusted curves, 14% of
patients receiving aripiprazole, 12% of patients taking risperidone, and 9% of patients
receiving olanzapine were readmitted by one-year after discharge. In comparison, the
unadjusted model shows that 8% of patients receiving quetiapine and 6% of patients
receiving ziprasidone were readmitted within the follow-up period. After using
inverse probability weighting, the adjusted curves show that 13% of patients receiving
risperidone, 12.5% of patients who were taking aripiprazole and 10% of patients
receiving olanzapine were readmitted by one-year after discharge. In comparison, 7%
of patients receiving quetiapine and 5.5% of patients receiving ziprasidone were
readmitted during the follow-up period.
3.5 Discussion
In the adjusted model, patients exposed to quetiapine and ziprasidone
demonstrated a lower risk (aHR=0.55; 95% CI=0.37, 0.81; aHR=0.55; 95% CI=0.29,
1.0, respectively) of readmission, compared to risperidone. As represented in Figure
3, choice of discharge atypical antipsychotic does have a significant association with
the risk of being readmitted for mental health treatment within the follow-up period in
pediatric patients after adjusting for baseline covariates. Pediatric patients receiving
quetiapine or ziprasidone also displayed a lower cumulative incidence of readmission
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(Figure 3) over study period compared to patients receiving risperidone at discharge,
after adjusting for baseline covariates

Risperidone is one of the most frequently

prescribed in the pediatric population for mental health treatment. This analysis
suggests that patients might be at a lower risk of relapse when treated with quetiapine
and ziprasidone and alternative AAP therapy may be more effective than risperidone.
A longer follow-up period is needed to compare effectiveness of atypical
antipsychotics.8

In addition, discharge from the hospital does not imply adherence to

the discharge medication therapy in the outpatient setting and this study did not
consider adherence. Risperidone might be poorly tolerated in this patient population
due to problematic side effects or poor therapeutic response. This could cause patients
to discontinue discharge therapy prior to the completion of the prescription. If patients
are no longer on risperidone discharge therapy, then the effect of this intervention on
readmission risk can be unclear. Future studies should examine discharge therapy
continuation to evaluate the role medication adherence in efficacy of discharge
AAPs.32
Female patients demonstrated a higher risk of one-year readmission for mental
health treatment compared to male patients. This differs from adult studies, that
indicated that gender was not a significant predictor of readmission.32,33 Patients who
were recently naïve to AAP medication therapy or received no treatment for the three
months prior to hospitalization were at a significantly higher risk of readmission at
one-year that patients receiving therapy prior to index admission (aHR=8.9; 95%
CI=3.7, 218). Often several therapies must be explored and tailored based on patient
response and side effects before a maintenance therapy can be established. Patients
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who had no recent exposure to AAP medication therapy could experience more
adverse medication reactions or incomplete therapeutic response, which can require
them to be readmitted for stabilization.
Our study focused on pediatric patients and many of the disease states
evaluated using the CCI are chronic in nature and more prevalent as age progresses, so
a majority of this pediatric study population (92%) demonstrated a CCI score of zero.
This was expected since the components of the CCI score are primarily chronic
illnesses and these conditions are usually present in higher frequencies as a population
ages. Most of the disease states analyzed in the CCI are chronic in nature (diabetes
complications, congestive heart failure, etc.) and do not occur frequently in children.
No specific comorbidity index is available and sufficiently validated for use in
pediatric patients, though there is forthcoming work for a pediatric-specific index.34
Disease states that are more prevalent in children, such as asthma, childhood leukemia
or autism, might be present in this cohort. However, the CCI index does not identify
these diagnoses and they are not factored into the overall score that is intended to
represent health status. Therefore, some underlying confounding by indication might
be present if the patients that experience a readmission are sicker at baseline, but the
disease severity is not fully captured by the CCI score. This study did not expressly
evaluate cost of admission or treatment, but length of hospitalization was included as a
covariate. Overall length of hospitalization can represent higher costs for the
admission and poorer long-term clinical outcomes for mental health treatment, so
overall length of stay (LOS) was examined as a covariate.20 Overall length of
hospitalization can represent higher costs for the admission and poorer long-term
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clinical outcomes for mental health treatment, so overall length of stay (LOS) was
examined as a covariate and was defined as a continuous variable for number of days
of admission.20
Based on the weighted cumulative incidence curves, the “other” category of
atypical antipsychotic agents trended toward a lower risk of readmission for mental
health treatment, when compared to risperidone. This class represents lurasidone,
asenapine, paliperidone, iloperidone and clozapine, all newer agents to the US market
or agents with no pediatric indication for use. Evidence for the efficacy of these
agents is limited in this study due to the low utilization of AAPs in this category.
Further studies with higher utilization of these newer agents are needed to better
understand this trend.
The model was stratified by gender and full results are presented in Appendix
D. The adjusted model for the entire cohort indicated possible unmeasured
confounding was present and some of underlying differences may be correlated with a
patient’s gender. After stratifying the model by gender, it was found that male
patients had a higher rate of risperidone use as a discharge AAP (32%) compared to
female patients (15%). Of note, male patients also had a higher rate of documented
disruptive and aggressive behavior (DAB) (12%) disorders than compared to female
patients (4%). Other demographics were similar between both groups in the study
cohort. Previous research in pediatric patients found AAP agents were use more often
in patients with documented DAB disorders (37.8%) compared to other mental health
diagnoses.1 Risperidone is one of the only AAP agents with a specific pediatric
indication for use in DAB disorders. Both factors could explain the differences in
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AAP selection and mental health diagnosis in the male portion of the study cohort.
Overall, the findings of readmission risk were similar for all other covariates in the
models separated by gender, except for discharge AAP. In the complete, adjusted
model, the risk of readmission for patients given zisprasidone was 45% lower
compared to risperidone (aHR=0.55, 95% CI=0.29, 1.0). Also, patients given
quetiapine had a 45% lower risk of readmission compared to risperidone (aHR=0.55,
95% CI=0.37, 0.81). Once stratified by gender, female patients given zisprasidone
had a 37% lower risk and male patients given zisprasidone had a 65% lower risk
(aHR=0.63, 95% CI=0.30, 1.3; aHR=0.35, 95% CI=0.08, 1.4) , respectively). This
decreased risk with zisprasidone compared to risperidone no longer reached the level
of significant. When stratified by gender, female patients given quetiapine had a 48%
lower risk of readmission and male patients given quetiapine had a 36% lower risk of
readmission (aHR=0.52, 95% CI=0.31, 0.88; aHR=0.64, 95% CI=0.4, 1.0,
respectively). This association remained significant, even when stratified by gender.
The association between discharge AAP agent and risk of readmission was somewhat
attenuated within each gender.
3.6 Limitations
This study only evaluated AAP medication therapy received upon discharge
from a mental health hospital admission. The permanence of this therapy or switches
in treatment was not evaluated. This study only evaluated the exposure to an agent at
the time of discharge and other therapies within the follow up time were not evaluated.
This could lead to exposure misclassification. Therapy switching and therapy
permanence (PDC) between discharge and readmission should be analyzed to
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determine if certain oral AAP therapies are more effective. This study examined the
difference in one-year hazard of readmission after prescribed an atypical antipsychotic
agent at discharge. The “other” category trended toward a lower risk of readmission,
but the use of these newer agents was low, and the determination of efficacy warrants
further study. Once these new agents are utilized in clinical practice, future studies
can evaluate evidence in administrative claims databases and determine if these agents
are effective at lowering the risk of readmission. Some unmeasured confounding
might be present for variables that we were unable to capture or did not examine in
this study. Combination therapy with multiple AAPs or compliance with counseling
or behavioral therapy has been documented to improve clinical outcomes and prevent
relapse.15,17 This study focused on analyzing the impact of discharge medication
therapy with AAPs on risk of readmission, so switching therapy or combination
therapy was not evaluated at this time. Mental health treatment often includes
counseling services and other behavioral therapy interventions. This study analyzed
the impact of medication therapy interventions on readmission outcomes specifically
and did not explore the impact of other treatment modalities. Mental health treatment
is often multifaceted and patient success is dependent on many treatment modalities.
Therapy services and group counseling provide support to the patient and play a vital
role, along with medications, to treatment success. These treatment options and
combinations of therapy with medications were not examined in this study but should
be included in future research for their impact on mental health treatment success.
3.7 Conclusions
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Patients receiving quetiapine and ziprasidone had a lower risk of readmission,
compared to risperidone when used at discharge in pediatric patients. Newer atypical
antipsychotic agents trended toward demonstrating a lower risk of readmission and
future studies are warranted to see if these agents have a significant effect on
readmission in pediatric patients. The cumulative incidence of readmission was lower
in patients receiving quetiapine and ziprasidone upon discharge, compared to
risperidone. Quetiapine and ziprasidone might want to be considered for increased use
in clinical practice for in pediatric patients to reduce the risk of readmission for mental
health treatment. Pediatric female patients had a significantly higher risk of
readmission for mental health treatment. Patients with no prior exposure to AAP
mediation therapy in the 3-month prior to index admission were at a much higher risk
of readmission for mental health treatment. Further studies are warranted to evaluate
factors, such as adverse events and therapy compliance, that might further mediate this
increased risk.
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Figure 1. Selection of US Pediatric Privately-Insured Patients (2 to 17 years) for Analyses of Oral
Atypical Antipsychotic Agents and Risk of Readmission for Mental Health Treatment (2010 to
2015)
18,928 patients aged 2-17 years
with inpatient admission
2,740 without continuous
eligibility during study period
16,188 patients with continuous
eligibility and inpatient admission
12,973 patients with no AAP paid
claim within discharge window

3,215 patients with inpatient
admission and at least 1 paid claim
for AAP within 14 days of discharge
131 patients with no admission for
Mental Health diagnosis
3,084 pediatric patients with
continuous eligibility and at least one
inpatient admission (index) for
mental health treatment

2,771 subjects with only index
admission (event=0)

313 patients with inpatient
readmission within 1 year of
discharge for mental health
treatment (event=1)
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Table 1. Demographic and Clinical Characteristics of Privately-Insured, US Children (2 to 17
years) with an Index Inpatient Admission for Mental Health Treatment from 2010 to 2015 by
Readmission Status (N=3,084)
Characteristic

Children with no
readmission (N=2,771)
14.7 (14.6,14.8)
8.0 (7.5, 8.6)

p-value

Patient Age, Years, Mean+ SD
Length of Stay (LOS, days)

Children with
readmission (N=313)
15.2 (15.0, 15.5)
8.2 (7.3, 9.1)

Follow Time, (days), Median (Q1, Q3)

95.3 (84, 107)

308 (304, 312)

<0.001

Age Group (years) N (%)*

0.002
0.85

0.0032

2-12 years

30 (9.6)

441 (15.9)

13-17 years (adolescents)

283 (90.4)

2330 (84.1)

Patient Gender, N (%)

<0.001

Male

128 (40.9)

1489 (53.7)

Female

185 (59.1)

1282 (46.3)

Patient Region, N (%)

0.60

Northeast
36 (11.5)
264 (9.5)
Midwest
87 (27.8)
810 (29.2)
South
135 (43.1)
1247 (45.0)
West
55 (17.6)
450 (16.2)
MH Diagnosis Category, N (%)
Anxiety Disorder
21 (6.7)
145 (5.2)
Mood Disorders
240 (76.7)
1996 (72.0)
Disruptive or Aggressive Behavior
15 (4.8)
238 (8.6)
Disorders
Developmental Disorders
4 (1.3)
119 (43)
Psychotic Disorders
3 (1.0)
78 (2.8)
Other MH Disorders
30 (9.6)
195 (7.0)
Prior AAP exposure
No prior AAP exposure at index
287 (91.7)
1653 (59.7)
admission
Treatment with same AAP as discharge
21 (6.7)
779 (28.1)
(index admission)
Treatment with different AAP as
5 (1.6)
339 (12.2)
discharge (index admission)
Discharge Atypical Antipsychotic Agent
Risperidone (Risperdal)
82 (26.2)
653 (23.6)
Quetiapine (Seroquel)
41 (13.1)
482 (17.4)
Aripiprazole (Abilify)
157 (50.2)
1138 (41.1)
Ziprasidone (Geodon)
11 (3.5)
175 (6.3)
Olanzapine (Zyprexa)
18 (5.8)
205 (7.4)
Other*
4 (1.3)
117 (4.2)
Charlson Comorbidity Score (on Index admission)
0
289 (92.3)
2567 (92.6)
1
24 (7.7)
202 (7.3)
2
0 (0)
2 (0.08)
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine
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0.002

<0.001

0.011

0.86

Table 2. Baseline Demographic and Clinical Characteristics of Privately Insured, US Children (2
to 17 years) with Index Inpatient Admission for Mental Health Treatment from 2010 to 2015,
Analyzed by Discharge Atypical Antipsychotic. (N=3,084)
Variable

Risperidone
(N=735)
13.6 (2.8)

Quetiapine
(N=523)
15.2 (2.1)

Aripiprazole
(N=1295)
14.7 (2.3)

Patient Age, Years,
Mean (SD)
Length of Stay
7.5 (7.6)
7.9 (6.0)
7.9 (18.7)
(LOS, days),
Follow time, Days,
286 (126)
298 (118)
280 (125)
Mean (SD)
Age Group (years) n (%)
2-12
204 (27.8)
46 (8.8)
159 (12.3)
13-17
531 (72.2)
477 (91.2)
1136(87.7
Patient Gender n (%)
Male
514 (69.9)
226 (43.2)
618 (47.7)
Female
221 (30.1)
297 (56.8)
677 (52.3)
Patient Region, n (%)
Northeast
83 (11.3)
45 (8.6)
141 (10.9)
Midwest
246 (33.5)
162 (31.0)
341 (26.3)
South
311 (42.3)
209 (40.0)
624 (48.2)
West
95 (12.9)
107 (20.5)
189 (14.6)
MH Diagnosis Category, n (%)
Anxiety Disorder
55 (7.5)
23 (4.4)
61 (4.7)
Mood Disorder
461 (62.7)
416 (79.5)
985 (76.1)
DAB Disorders
101 (13.7)
20 (3.8)
91 (7.0)
Developmental
44 (6.0)
6 (1.2)
38 (2.9)
Disorders
Psychotic Disorders
26 (3.5)
9 (1.7)
25 (1.9)
Other MH Disorders 48 (6.5)
49 (9.4)
95 (7.3)
Prior AAP Exposure, n (%)
No prior AAP
473 (64.4)
354 (67.7)
839 (64.8)
exposure
Treatment with
187 (25.4)
104 (19.9)
385 (29.7)
same AAP as
discharge (index
admission)
Treatment with
75 (10.2)
65 (12.4)
71 (5.5)
different AAP as
discharge (index
admission)
Charlson Comorbidity Score (On Index Admission), n (%)
0
685 (93.2)
485 (92.7)
1189 (91.8)
1
50 (6.8)
38 (7.3)
105 (8.1)
2
0 (0)
0 (0)
1 (0.1)

Ziprasidone
(N=186)
14.6 (2.2)

Olanzapine
(N=223)
14.3 (2.5)

Other*
(N=121)
14.6 (2.2)

p-value

8.5(8.0)

8.6 (6.1)

12.9 (29.0)

0.006

298 (117)

287 (126)

293 (118)

0.05

21 (11.3)
165 (88.7)

31 (13.9)
192 (86.1)

10 (8.3)
111 (91.7)

82 (44.1)
104 (55.9)

124 (55.6)
99 (44.4)

53 (43.8)
68 (56.2)

14 (7.5)
56 (30.1)
91 (48.9)
25 (13.4)

8 (3.6)
54 (24.2)
84 (37.7)
77 (34.5)

9 (7.4)
37 (30.6)
63 (52.1)
12 (9.9)

3 (1.6)
140 (75.3)
16 (8.6)
12 (6.5)

17 (7.6)
145 (65.0)
17 (7.6)
18 (8.1)

7 (5.8)
88 (72.7)
8 (6.6)
5 (4.1)

7 (3.8)
8 (4.3)

8 (3.6)
18 (8.1)

6 (5.0)
7 (5.8)

92 (49.5)

132 (59.2)

49 (40.5)

55 (29.6)

34 (15.3)

35 (28.9)

39 (21.0)

57 (25.6)

37 (30.6)

171 (91.9)
15 (8.1)
0 (0)

212 (95.1)
10 (4.5)
1 (0.4)

113 (93.4)
8 (6.6)
0 (0)

<0.001

<0.001

<0.001

<0.001

<0.001

0.41

*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine
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<0.001

Table 3. Unadjusted and Adjusted Hazard Ratios of Readmission derived from a Cox
Proportional Hazards Model for Privately-Insured US Children (2 to 17 years) with an Index
Admission for Mental Health Treatment, in database 2010 to 2015 (N=3,084)
Variable
Index Admission, Length of Stay
(LOS)
Age Group

Hazard Ratio
(95 CIs)
1.0 (0.99, 1.02)

P-value

Hazard Ratios
(Adjusted)

p-value

0.88
0.007

2-12 years

1.7 (1.2, 2.5)

13-17 years

Reference

Patient Gender

Violated the proportional
hazards assumption. Model
stratified on age, so no hazard
ratio generated
<0.001

0.002

Female

1.6 (1.3, 2.1)

1.5 (1.2, 1.8)

Male

Reference

Reference

Patient Region
0.84
Northeast
1.1 (0.71, 1.7)
Midwest
0.86 (0.6, 1.2)
West
0.83 (0.6, 1.2)
South
Reference
MH Diagnosis Category
0.35
Anxiety Disorder
1.3 (0.77, 2.3)
1.1 (0.60, 1.9)
Mood Disorders
1.0 (0.71, 1.5)
0.83 (0.57, 1.2)
Disruptive or Aggressive Behavior 0.45 (0.23, 0.89)
0.58 (0.31, 1.1)
Disorders
Developmental Disorders
0.35 (0.12, 0.98)
0.37 (0.12, 1.1)
Psychotic Disorders
0.50 (0.18, 1.4)
0.36 (0.11, 1.2)
Other MH Disorders
Reference
Reference
Prior AAP exposure
<0.001
No prior AAP exposure
10.2 (4.2, 24.7)
8.9 (3.7, 21.8)
Treatment with same AAP as
1.8(0.66, 4.7)
1.6 (0.6, 4.2)
discharge (index admission)
Treatment with different AAP as
Reference
Reference
discharge (index admission)
Discharge Atypical Antipsychotic
0.14
Agent
Risperidone (Risperdal)
Reference
Reference
Quetiapine (Seroquel)
0.69 (0.47, 1.0)
0.55 (0.37, 0.81)
Aripiprazole (Abilify)
1.1 (0.84, 1.4)
0.93 (0.71, 1.2)
Ziprasidone (Geodon)
0.52 (0.28, 0.97)
0.55 (0.29, 1.0)
Olanzapine (Zyprexa)
0.72 (0.43, 1.2)
0.73 (0.43, 1.2)
Other*
0.29 (0.11, 0.79)
0.35 (0.13, 0.97)
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine
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0.14

<0.001

0.006

Figure 2. Unadjusted Cumulative Probability of Readmission from 2010 to 2015 for Mental
Health Treatment by AAP Medication at Discharge, in US Privately-Insured Children (2 to 17
years) from 2010 to 2015 (N=313)

Figure 3. Weighted Cumulative Probability of Readmission from 2010 to 2015 for Mental Health
Treatment by Atypical Antipsychotic Medication at Discharge, in Privately-Insured US Children
(2 to 17 years) from 2010 to 2015 (N=313)
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APPENDIX A
MENTAL HEALTH DIAGNOSES OF INTEREST FOR STUDY
POPULATION
International Classification of Disease 9th Edition [ICD-9] medical codes (2012)
International Classification of Disease 10th Edition [ICD-10] medical codes (2017)
(Halloran, Swindle, Takemoto, & Schnitzler, 2010; Olfson, King, & Schoenbaum, 2015; Patel,
Crismon, & Shafer, 2006)

Diagnosis

ICD-9-CM

ICD-10-CM

Anxiety Disorders

300-300.3, 300.5-300.9, 309.2x, 309.4,

F40-F48

309.81, 313.0

Mood Disorders

296, 300.4, 301.1x, 309.0, 309.1, 311, 313.1

F30-F39

Disruptive/aggressive

309.3, 312.xx, 313.81, 314.xx, V40.3, V40.9

F90-F98

299.0, 315-319, V40.0-V40.2, V79.2

F70-F79, F80-F89

292.1x, 293-295.9, 297-298.9, 299, 299.1-

F20-F29

Behavior disorders
Developmental
Disorders
Psychotic Disorders

299.91, 368.16, 780.1

Miscellaneous/Other
Disorders

290-292.0, 292.2-292.2, 301-301.0, 301.2307.59, 307.8-309, 309.8, 309.82-310.9, 313,
313.2-313.8, 313.82-313.9, 660-331.9, V66.3,
V67.3, V71.0
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F99, F50-F59, F60F69

APPENDIX B
ATPYICAL ANTIPSYCHOTIC AGENTS AVAILABLE ON US MARKET
(“Drugs@FDA: FDA Approved Drug Products,” 2017)

Medication
Risperidone

Olanzapine
Aripiprazole

Paliperidone
Quetiapine
Ziprasidone
Lurasidone
Clozapine
Iloperidone
Asenapine

FDA pediatric indication

Year of Indication
Approval
Schizophrenia (13-17 yrs.)
2007
Bipolar I (10-17 yrs.)
2007
Irritability with Autistic Disorder (5-16 yrs.) 2007
Schizophrenia (13-17 yrs.)
2010
Bipolar I (13-17 yrs.)
2009
Schizophrenia (13-17 yrs.)
2007
Bipolar I (10-17 yrs.)
2008
Irritability with Autistic Disorder (6-17 yrs.) 2009
Schizophrenia (12-17 yrs.)
2011
Schizophrenia (13-17 yrs.)
2009
Bipolar I (10-17 yrs.)
2009
None
none
Schizophrenia (13-17 yrs.)
2017
None
None
None
None
Bipolar I (10-18 yrs.)
2015
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APPENDIX C
CHARLSON COMORBIDITY INDEX, DIAGNOSTIC CATEGORIES
(Sundararajan et al., 2004)

Condition
Acute myocardial
infarction
Congestive Heart
Failure
Peripheral vascular
Disease

Weights
1

ICD-9-CM Codes
410, 412

ICD-10-CM Codes
121, 122, 125.2

1

428

1

441, 4439, 7854, V4334

Cerebral vascular
accident
Dementia
Pulmonary disease

1

430-438

109.9, 111, 113, 113.2, 125.5, 142,
142.5-142.9, 143, 150, P29
170, 171, 173, 173.8, 173.9, 177.1,
179-179.2, K55.1, K55.8, K55.9,
295.8, 295.9
G45, G46, H34, 160-169

1
1

Connective tissue
disorder

1

Peptic ulcer
Liver disease

1
1

290
490, 491, 492, 493, 494,
495, 496, 500, 501, 502,
503, 504, 505
7100, 7101, 7104, 7140,
7141, 7142, 71481 (now
5171), 725
531, 532, 533, 534
5712, 5714, 5715, 5716

Diabetes

1

2500, 2501, 2502, 2503,
2507

Diabetes
complications

2

2504, 2505, 2506

Paraplegia

2

342, 3441

Renal disease

2

Cancer

2

Metastatic cancer
Severe liver disease

3
3

285, 2830, 5831, 5832,
5833, 5835, 5836, 5837,
5834, 5855, 86588
14, 15, 16, 18, 170, 171,
172, 174, 175, 176,179,
190, 192, 193, 194, 1950,
1951, 1952, 1953, 1954,
1955, 1958, 200, 201, 202,
203, 204, 205, 206,
207,208
196, 197, 198, 1990, 1991
5722, 5723, 5724, 5728

HIV

6

042, 043, 044
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F00-F03, F05, G30, G31
127.8, 127.9, 140-147, 160-167,
J68.4, J70.1, J70.3
M05, M06, M31.5, M32-M34,
M35.1, M35.3, M36.0
K25-K28
B18, K70.0-K70.3, K70.9, K71.3K71.5, K71.7, K73, K74, K76.0,
K76.2-K76.4, K76.8, K76.9, Z94.4
E10.0, E10.l, E10.6, E10.8, E10.9,
E11.0, E11.1, E11.6, E11.8, E11.9,
E12.0, E12.1, E12.6, E12.8, E12.9,
E13.0, E13.1, E13.6, E13.8, E13.9,
E14.0, E14.1, E14.6, E14.8, E14.9
E10.2-E10.5, E10.7, E11.2-E11.5,
E11.7, E12.2-E12.5, E12.7, E13.2E13.5, E13.7, E14.2-E14.5, E14.7
G04.1, G11.4, G80.1, G80.2, G81,
G82, G83.0-G83.4, G83.9
I12.0, I13.1, N03.2-N03.7, N05.2N05.7, N18, N19, N25.0, Z49.0Z49.2, Z94.0, Z99.2
C00-C26, C30-C34, C37-C41, C43,
C45-C58, C60-C76, C81-C85, C88,
C90-C97

C77-C80
I85.0, I85.9, I86.4, I98.2, K70.4,
K71.1, K72.1, K72.9, K76.5,
K76.6, K76.7
B20-B22, B24

APPENDIX D
STUDY 3 RESULTS: STRATIFIED BY GENDER
Demographic and Clinical Characteristics of Privately-Insured, Male, US Children (2 to 17 years)
with an Index Inpatient Admission for Mental Health Treatment from 2010 to 2015 by
Readmission Status (N=1,617)
Characteristic

Children with no
readmission
(N=1,489)
14.3 (14.2, 14.5)
8.4 (7.4, 9.4)

p-value

Patient Age, Years, Mean+ SD
Length of Stay (LOS, days)

Children with
readmission
(N=128)
14.8 (14.3, 15.2)
7.3 (6.2, 8.4)

Follow Time, (days), Median (Q1, Q3)

97.2 (78.4, 116)

309 (304, 314)

<0.001

Age Group (years) N (%)*

0.06
0.54

0.11

2-12 years

21 (16.4)

335 (22.5)

13-17 years (adolescents)

107 (83.6)

1154 (77.5)

Patient Region, N (%)

0.12

Northeast
20 (115.6)
137 (9.2)
Midwest
39 (30.5)
458 (30.8)
South
50 (39.1)
645 (43.3)
West
19 (14.8)
249 (16.7)
MH Diagnosis Category, N (%)
Anxiety Disorder
10 (7.8)
66 (4.4)
Mood Disorders
92 (71.9)
979 (65.8)
Disruptive or Aggressive Behavior
12 (9.4)
186 (12.5)
Disorders
Developmental Disorders
3 (2.3)
95 (6.4)
Psychotic Disorders
3 (2.3)
58 (3.9)
Other MH Disorders
8 (6.3)
105 (92.9)
Prior AAP exposure
No prior AAP exposure at index
116 (90.6)
841 (56.5)
admission
Treatment with same AAP as discharge
10 (7.8)
456 (30.6)
(index admission)
Treatment with different AAP as
2 (1.6)
192 (12.9)
discharge (index admission)
Discharge Atypical Antipsychotic Agent
Risperidone (Risperdal)
50 (39.1)
464 (31.2)
Quetiapine (Seroquel)
15 (11.7)
211 (14.2)
Aripiprazole (Abilify)
54 (42.2)
564 (37.9)
Ziprasidone (Geodon)
2 (1.6)
80 (5.4)
Olanzapine (Zyprexa)
6 (4.7)
118 (7.9)
Other*
1 (0.8)
52 (3.5)
Charlson Comorbidity Score (on Index admission)
0
118 (92.2)
1375 (92.3)
1
10 (7.8)
112 (7.5)
2
0 (0)
2 (0.13)
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine
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0.13

<0.001

0.05

0.91

Baseline Demographic and Clinical Characteristics of Privately Insured, Male, US Children (2 to
17 years) with Index Inpatient Admission for Mental Health Treatment from 2010 to 2015,
Analyzed by Discharge Atypical Antipsychotic. (N=1,617)
Variable

Risperidone
(N=514)
13.9 (2.7)

Quetiapine
(N=226)
15.3 (1.9)

Aripiprazole
(N=618)
15.0 (2.1)

Patient Age,
Years, Mean
(SD)
Length of Stay 7.5 (7.6)
8.5 (10)
7.2 (6.9)
(LOS, days),
Follow time,
289 (124)
299 (117)
292 (119)
Days, Mean
(SD)
Age Group (years) n (%)
2-12
164 (32.0)
27 (12.0)
117 (29.0)
13-17
350 (68.0)
199 (88.0)
501 (81.0)
Patient Region, N (%)
Northeast
56 (10.9)
20 (8.9)
67 (10.8)
Midwest
177 (34.4)
70 (31.0)
173 (28.0)
South
215 (41.8)
84 (37.2)
291 (47.1)
West
66 (12.8)
52 (23.0)
87 (14.1)
MH Diagnosis Category, n (%)
Anxiety
32 (6.2)
5 (2.2)
31 (5.0)
Disorder
Mood
301 (58.6)
175 (77.4)
425 (68.8)
Disorder
DAB
87 (16.9)
12 (5.3)
70 (11.3)
Disorders
Developmental 33 (6.4)
5 (2.2)
35 (5.7)
Disorders
Psychotic
23 (4.5)
4 (1.8)
21 (3.4)
Disorders
Other MH
38 (7.4)
25 (11.1)
36 (5.8)
Disorders
Prior AAP Exposure, n (%)
No prior AAP
322 (62.7)
144 (63.7)
364 (58.9)
exposure
Treatment with 135 (26.3)
53 (23.5)
214 (34.6)
same AAP as
discharge
(index
admission)
Treatment with 57 (11.1)
29 (12.8)
40 (6.5)
different AAP
as discharge
(index
admission)
Charlson Comorbidity Score (On Index Admission), n (%)
0
483 (94.0)
209 (92.5)
563 (91.1)
1
31 (6.0)
17 (7.5)
54 (8.7)
2
0 (0)
0 (0)
1 (0.2)

Ziprasidone
(N=82)
15.1 (1.9)

Olanzapine
(N=124)
14.7 (2.2)

Other*
(N=53)
15.3 (1.8)

p-value

7.8 (6.4)

8.6 (6.1)

11.1 (19.8)

0.008

298 (115)

291 (114)

0.92

15 (18.3)
67 (81.7)

23 (18.6)
101 (81.5)

10 (18.9)
43 (81.1)

5 (6.1)
23 (28.1)
41 (50.0)
13 (15.9)

5 (4.0)
33 (26.6)
40 (32.3)
46 (37.1)

4 (7.6)
21 (39.6)
24 (45.3)
4 (7.6)

1 (1.2)

4 (3.2)

3 (5.7)

56 (68.3)

80 (64.5)

34 (64.2)

9 (11.0)

14 (11.3)

6 (11.3)

9 (11.0)

11 (8.9)

5 (9.4)

3 (3.7)

7 (5.7)

3 (5.7)

4 (4.9)

8 (6.5)

2 (3.8)

33 (40.2)

75 (60.5)

19 (35.9)

29 (35.4)

20 (16.1)

15 (28.3)

20 (24.4)

29 (23.4)

19 (35.9)

75 (91.5)
7 (8.5)
0 (0)

116 (93.6)
7 (5.7)
1 (0.8)

47 (88.7)
6 (11.3)
0 (0)

289 (123)

<0.001

<0.001

<0.001

<0.001

0.39

*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine
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<0.001

Unadjusted and Adjusted Hazard Ratios of Readmission based on a Cox Proportional Hazards
Model for Privately-Insured, Male, US Children (2 to 17 years) with an index admission for
Mental Health Treatment, in database 2010 to 2015 (N=1,617)
Variable
Index Admission, Length of Stay
(LOS)
Age Group

Hazard Ratio
(95 CIs)
1.0 (0.98, 1.0)

P-value

Hazard Ratios
(Adjusted)

p-value

0.51
0.13

2-12 years

1.4 (0.90, 2.3)

13-17 years

Reference

Violated the proportional
hazards assumption. Model
stratified on age, so no
hazard ratio generated

Patient Region
0.08
Northeast
Reference
Reference
Midwest
0.61 (0.36, 1.0)
0.55 (0.32, 0.95)
West
0.56 (0.33, 0.93)
0.44 (0.26, 0.74)
South
0.56 (0.30, 1.0)
0.45 (0.23, 0.85)
MH Diagnosis Category
0.13
Anxiety Disorder
2.0 (0.78, 5.0)
1.1 (0.60, 1.9)
Mood Disorders
1.2 (0.58, 2.5)
0.83 (0.57, 1.2)
Disruptive or Aggressive Behavior 0.84 (0.34, 2.0)
0.58 (0.31, 1.1)
Disorders
Developmental Disorders
0.41 (0.11, 1.5)
0.37 (0.12, 1.1)
Psychotic Disorders
0.64 (0.17, 2.4)
0.36 (0.11, 1.2)
Other MH Disorders
Reference
Reference
Prior AAP exposure
<0.001
No prior AAP exposure
12.2 (3.0, 49.4)
10.3 (2.5, 42.0)
Treatment with same AAP as
2.1 (0.46, 9.6)
1.8 (0.4, 8.2)
discharge (index admission)
Treatment with different AAP as
Reference
Reference
discharge (index admission)
Discharge Atypical Antipsychotic
0.09
Agent
Risperidone (Risperdal)
Reference
Reference
Quetiapine (Seroquel)
0.67 (0.37, 1.2)
0.64 (0.4, 1.0)
Aripiprazole (Abilify)
0.89 (0.60, 1.3)
0.90 (0.61, 1.3)
Ziprasidone (Geodon)
0.25 (0.06, 1.0)
0.35 (0.08, 1.4)
Olanzapine (Zyprexa)
0.48 (0.21, 1.1)
0.53 (0.22, 1.2)
Other*
0.19 (0.03, 1.4)
0.29 (0.04, 2.1)
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine
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0.02

0.27

<0.001

0.26

Demographic and Clinical Characteristics of Privately-Insured, Female, US Children (2 to 17
years) with an Index Inpatient Admission for Mental Health Treatment from 2010 to 2015 by
Readmission Status (N=1,467)
Characteristic

Children with no
readmission
(N=1,282)
15.2 (1.9)
7.7 (6.6)

p-value

Patient Age, Years, Mean+ SD
Length of Stay (LOS, days)

Children with
readmission
(N=185)
15.5 (1.8)
8.8 (8.9)

Follow Time, (days), Median (Q1, Q3)

93.9 (97.5)

307 (107)

<0.001

Age Group (years), n (%)*

0.11
0.04

0.11

2-12 years

9 (4.9)

106 (8.3)

13-17 years (adolescents)

176 (95.1)

1176 (91.7)

Patient Region, n (%)

0.60

Northeast
16 (8.7)
127 (9.9)
Midwest
48 (26.0)
352 (27.5)
South
85 (46.0)
602 (47.0)
West
36 (19.5)
201 (15.7)
MH Diagnosis Category, n (%)
Anxiety Disorder
11 (6.0)
79 (6.2)
Mood Disorders
148 (80)
1017 (79.3)
Disruptive or Aggressive Behavior
3 (1.6)
52 (4.1)
Disorders
Developmental Disorders
1 (0.5)
24 (1.9)
Psychotic Disorders
0 (0)
20 (1.6)
Other MH Disorders
22 (11.9)
90 (7.0)
Prior AAP exposure, n (%)
No prior AAP exposure at index
171 (92.4)
812 (63.3)
admission
Treatment with same AAP as discharge
11 (6.0)
323 (25.2)
(index admission)
Treatment with different AAP as
3 (1.6)
147 (11.5)
discharge (index admission)
Discharge Atypical Antipsychotic Agent, n (%)
Risperidone (Risperdal)
32 (17.3)
189 (14.8)
Quetiapine (Seroquel)
26 (14.1)
271 (21.2)
Aripiprazole (Abilify)
103 (55.7)
574 (44.8)
Ziprasidone (Geodon)
9 (4.9)
95 (7.4)
Olanzapine (Zyprexa)
12 (6.5)
87 (6.8)
Other*
3 (1.6)
65 (5.1)
Charlson Comorbidity Score (on Index admission), n (%)
0
171 (92.4)
1192 (93.0)
1
14 (7.6)
90 (7.0)
2
0
0
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine
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0.033

<0.001

0.01

0.79

Baseline Demographic and Clinical Characteristics of Privately Insured, Female, US
Children (2 to 17 years) with Index Inpatient Admission for Mental Health Treatment from 2010
to 2015, Analyzed by Discharge Atypical Antipsychotic. (N=1,467)
Variable

Risperidone
(N=221)
14.6 (2.5)

Quetiapine
(N=297)
15.4 (1.7)

Aripiprazole
(N=677)
15..4 (1.7)

Patient Age,
Years, Mean
(SD)
Length of Stay
7.6 (7.3)
8.0 (5.7)
7.4 (7.2)
(LOS, days),
Follow time,
278 (128)
298 (119)
268 (130)
Days, Mean
(SD)
Age Group (years) n (%)
2-12
40 (18.1)
19 (6.4)
42 (6.2)
13-17
181 (81.9)
278 (93.6)
635 (93.8)
Patient Region, N (%)
Northeast
27 (12.2)
25 (8.4)
74 (10.9)
Midwest
69 (31.2)
92 (31.0)
168 (24.8)
South
96 (43.4)
125 (42.1)
333 (49.2)
West
29 (13.1)
55 (18.5)
102 (15.1)
MH Diagnosis Category, n (%)
Anxiety
23 (10.4)
18 (6.1)
30 (4.4)
Disorder
Mood Disorder
160 (72.4)
241 (81.1)
560 (82.7)
DAB Disorders
14 (6.3)
8 (2.7)
21 (3.1)
Developmental
11 (5.0)
1 (0.3)
3 (0.4)
Disorders
Psychotic
3 (1.4)
5 (1.7)
4 (0.6)
Disorders
Other MH
10 (4.5)
24 (8.1)
59 (8.7)
Disorders
Prior AAP Exposure, n (%)
No prior AAP
151 (68.3)
210 (70.7)
475 (70.2)
exposure
Treatment with
52 (23.5)
51 (17.2)
171 (11.7)
same AAP as
discharge (index
admission)
Treatment with
18 (8.1)
36 (12.1)
31 (4.6)
different AAP as
discharge (index
admission)
Charlson Comorbidity Score (On Index Admission), n (%)
0
202 (91.4)
276 (92.9)
626 (92.5)
1
19 (8.6)
21 (7.1)
51 (7.5)
2
0
0
0

Ziprasidone
(N=104)
15.5 (1.7)

Olanzapine
(N=99)
15.2 (1.9)

Other*
(N=68)
15.7 (1.2)

p-value

9.0 (8.2)

8.3 (6.4)

9.0 (7.1)

0.16

274 (137)

294 (122)

0.003

6 (5.8)
98 (94.2)

8 (8.1)
91 (91.9)

0 (0.0)
68 (100)

9 (8.7)
33 (31.7)
50 (48.1)
12 (11.5)

3 (3.0)
21 (21.2)
44 (44.4)
31 (31.3)

5 (7.4)
16 (23.5)
39 (57.4)
8 (11.8)

2 (1.9)

13 (13.1)

4 (5.9)

84 (80.8)
7 (6.7)
3 (2.9)

65 (65.7)
3 (3.0)
7 (7.1)

54 (79.4)
2 (2.9)
0 (0.0)

4 (0.3)

1 (1.0)

3 (4.4)

4 (3.9)

10 (10.1)

5 (7.4)

59 (56.7)

57 (57.6)

30 (44.1)

26 (25.0)

14 (14.1)

20 (29.4)

19 (18.3)

28 (28.3)

18 (26.5)

96 (92.3)
8 (7.7)
0

96 (97.0)
3 (3.0)
0

66 (97.1)
2 (2.9)
0

306 (112)

<0.001

<0.001

<0.001

<0.001

0.38

*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine
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<0.001

Unadjusted and Adjusted Hazard Ratios of Readmission based on a Cox Proportional Hazards
Model for Privately-Insured, Female, US Children (2 to 17 years) with an index admission for
Mental Health Treatment, in database 2010 to 2015 (N=1,467)
Variable
Index Admission, Length of Stay
(LOS)
Age Group

Hazard Ratio
(95 CIs)
1.0 (0.99, 1.02)

P-value

Hazard Ratios
(Adjusted)

p-value

0.88
0.16

2-12 years

1.6 (0.83, 3.2)

13-17 years

Reference

Violated the proportional
hazards assumption. Model
stratified on age, so no
hazard ratio generated

Patient Region
0.65
Northeast
Reference
Midwest
1.1 (0.62, 1.9)
West
1.1 (0.66, 1.9)
South
1.4 (0.76, 2.5)
MH Diagnosis Category
0.13
Anxiety Disorder
0.60 (0.29, 1.2)
0.70 (0.34, 1.5)
Mood Disorders
0.62 (0.40, 0.97)
0.70 (0.42, 1.0)
Disruptive or Aggressive Behavior 0.26 (0.08, 0.87)
0.33 (0.1, 1.1)
Disorders
Developmental Disorders
0.19 (0.03, 1.4)
0.41 (0.05, 3.1)
Psychotic Disorders
0
0
Other MH Disorders
Reference
Reference
Prior AAP exposure
<0.001
No prior AAP exposure
9.5 (3.1, 29.9)
8.9 (3.7, 21.8)
Treatment with same AAP as
1.7 (0.47, 6.1)
1.6 (0.6, 4.2)
discharge (index admission)
Treatment with different AAP as
Reference
Reference
discharge (index admission)
Discharge Atypical Antipsychotic
0.02
Agent
Risperidone (Risperdal)
Reference
Reference
Quetiapine (Seroquel)
0.59 (0.35, 0.98)
0.52 (0.31, 0.88)
Aripiprazole (Abilify)
1.1 (0.72, 1.6)
0.99 (0.66, 1.5)
Ziprasidone (Geodon)
0.57 (0.27, 1.2)
0.63 (0.30, 1.3)
Olanzapine (Zyprexa)
0.86 (0.44, 1.7)
0.87 (0.44, 1.7)
Other*
0.30 (0.09, 0.96)
0.39 (0.12, 1.3)
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine
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0.41

<0.001

0.035

